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ACETAZOLAMIDE IN THE TREATMENT OF ACUTE MOUNTAIN SICKNESS: CLINICAL 
EFFICACY AND EFFECT ON GAS EXCHANGE. Colin K. Grissom, Robert C. 
Roach, and Peter H. Hackett. Denali Medical Research Project, 
University of Alaska, Anchorage. David H. Ingbar, Pulmonary 
Section, Yale University School of Medicine. 
Acute mountain sickness (AMS) is a neurologic syndrome that 
occurs upon ascent to high altitude, and is associated with 
impaired pulmonary gas exchange. Acetazolamide prevents AMS when 
given prior to ascent, but has not been proven effective for 
treatment. We therefore set out to determine: 1) the efficacy of 
acetazolamide for treatment of AMS and 2) the effect of 
acetazolamide on pulmonary gas exchange in AMS. Twelve climbers 
with AMS at 4200m on Mt. McKinley were randomized in a double blind 
fashion to acetazolamide (n=6) or placebo (n=6) . The dose of 
acetazolamide was 250 mg PO at 0 and 8 hours after inclusion in the 
study. Assessment of AMS and physical measurements were made at 
0 hours and were repeated at 24 hours. 
PLACEBO ACETAZOLAMIDE 
(mean _+SE) (mean _+SE) 
Symptom Score * n=6 n=6 
Baseline 3.8 +0.7 3.8 +0.2 
24 hours 2.5 +0.3 1.0 +0.2 ** 
A-a Gradient (torrs) n=6 n=3 
Baseline 8.8 +1.8 9.0 +1.6 
24 hours 12.1 +1.7 8.2 +1.9 
(change 0-24 hrs) (+3.3 +0.9) (-0.8 +0.7) *** 
Pa02 (torrs) n=6 n = 3 
Baseline 45.2 +1.3 44.2 +3.4 
24 hours 43.8 +2.0 47.1 +2.9 
(change 0-24 hrs) (-1.4 +1.2) (+2.9 +0.5) *** 
* A symptom score of 2 or greater indicated AMS. 
** pc.Ol acetazolamide versus placebo, Mann-Whitney U-test. 
*** p<.05 for change in A-a gradient and Pa02 over 24 hours between 
groups, Mann-Whitney Rank-Sum test. 
At 24 hours 5 of 6 acetazolamide-treated climbers were without 
AMS (symptom score <2), and all 6 placebo-treated climbers still 
had AMS (symptom score >2) . No significant side-effects of 
acetazolamide were reported. Acetazolamide improved pulmonary gas 
exchange and Pa02 over 24 hours as compared to placebo. Change in 
A-a gradient for 02 correlated significantly with change in symptom 
score for both groups (p<.005) . Acetazolamide was associated with 
a decrease in A-a gradient and a greater improvement in symptoms, 
and placebo was associated with an increase in A-a gradient and 
less improvement in symptoms. We conclude that acetazolamide is 
effective for the treatment of established cases of AMS, and is 
associated with an improvement in pulmonary gas exchange. 
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ALTITUDE CONVERSION AND BAROMETRIC PRESSURE 
Meters Feet 
Sea Level Sea Level 
1524 5000 
2134 7000 
2743 9000 
3353 11000 
3962 13000 
4572 15000 
5182 17000 
5791 19000 
6401 21000 
7010 23000 
7620 25000 
8230* 27000* 
8839** 29000** 
* There are 14 mountains in the 
** Elevation of Mt. Everest. 
Barometric Pressure (torr) 
760 
627 
581 
538 
497 
462 
426 
395 
366 
339 
314 
291 
269 
249 
world over 8000m in elevation. 
(Adapted from Hackett et. al. reference 35) 
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"In 1935 four of us, crossing a pass of only 17,000 ft. 
from Sikkim into Tibet, suffered extremely, and although 
carrying no loads were quite incapable of keeping pace 
with our transport which, since it included some yaks, 
was not exactly devouring the ground. Such discrepancies 
are difficult to explain and a great deal has yet to be 
learnt about acclimatisation." 
H.W. Tillman, from The Ascent of Nanda Devi. 
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I. INTRODUCTION 
Human populations have lived for centuries at elevations 
between 4000m and 5000m on the Tibetan plateau in Asia and on the 
high plateaus of Peru and Bolivia (47). The need for cultures to 
exchange goods led to the development of trade routes that 
traversed high mountain passes, and it was in this context that 
acute mountain sickness was first described in ancient China (70). 
Although the European population was well aware of the 
breathlessness experienced in the Alps, it was not until the early 
sixteenth century, during the Spanish invasion of the Incan empire 
in South America, that the extent of altitude illness became known 
to the western world (53) . Still, deaths among Spanish troops 
crossing high passes in the Andes were attributed to "the sickness 
of the Andes", or "soroche", and not to a specific effect of the 
air at high altitude. The Jesuit father Jose de Acosta, travelling 
in the Andes after the Conquistadors, was the first to attribute 
illness experienced crossing the high passes in the Andes "to the 
air and the wind blowing there". In an account of his experiences, 
The Natural and Moral History of the Indies, published in 1590 some 
forty years after his travels, Acosta gives a vivid description of 
altitude illness (3,47): 
"when I began to mount the stairs, as they call the 
highest part of this mountain, I was suddenly attacked 
and surprised by an illness so deadly and strange, that 
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I was almost on the point of falling from my horse to 
the ground ... I was seized by such a spasm of panting 
and vomiting that I thought I should give up the ghost. . . 
That lasted only three or four hours until we had 
descended pretty low and had reached a temperature more 
suited to nature" 
With the increasing numbers of individuals ascending to higher 
altitudes today, altitude illness has become more common and the 
study of altitude illness more relevant. Advances in passive 
transportation and an increased interest in activities such as 
sightseeing, skiing, hiking, and mountaineering combined with 
increased leisure time have brought more individuals to higher 
altitudes at faster rates of ascent. In 1984, over 34 million 
persons visited recreation areas above 2400m in Colorado and Utah. 
Hundreds of thousands annually visit Nepal, Tibet , and South 
America, many travelling to altitudes over 4000m (62) . All 
individuals ascending to altitude undergo the physiologic process 
of acclimatization and some individuals experience one of the forms 
of altitude illness. This encompasses a spectrum ranging from the 
more common acute mountain sickness (AMS) to the more life 
threatening high altitude pulmonary edema (HAPE) or high altitude 
cerebral edema (HACE). 
AMS is a symptom complex that is commonly seen in individuals 
a few hours to a few days after ascending to altitudes above 2500m 
(30,31). In the milder forms it is characterized by headache, 
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insomnia, malaise, and anorexia. In the more severe forms it is 
characterized by nausea, vomiting, ataxia, psychological changes, 
lassitude, and breathlessness (30,34) . AMS is generally self 
limited, although it can be incapacitating, and can progress to 
life threatening HAPE or HACE. With the increasing numbers of high 
altitude sojourners, knowledge of the pathophysiology, recognition, 
and treatment of acute altitude illness becomes more relevant, to 
increase both the enjoyment and safety of those travelling to high 
altitude areas. The purpose of this thesis is to review 
information relevant to altitude illness with particular attention 
to the syndrome of AMS, and then to present a study investigating 
the efficacy of acetazolamide in the treatment of AMS and its 
effect on gas exchange in AMS. This has important implications for 
the treatment of this most common form of altitude illness. 
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II. HIGH ALTITUDE ACCLIMATIZATION 
The initial insult in individuals ascending to altitude is a 
fall in the partial pressure of inspired oxygen (Pi02), resulting 
from a logarithmic fall in the barometric pressure with increasing 
altitude. The work of a French physiologist, Paul Bert, in the 
1870's proved that the effects of high altitude on the human body 
result from reduced partial pressure of oxygen, and not from 
isolated hypobaria. Until Bert's work, conducted on both men and 
animals in an altitude chamber, there had been a sharp divergence 
of opinion as to whether mountain sickness was due to diminished 
barometric pressure per se, or to diminished oxygen pressure. 
Bert's interest in high altitude physiology arose from both 
mountain journeys and the difficulties encountered by the 
balloonists of his day. Bert was in fact a sponsor of the ill 
fated ascent of the balloon "The Zenith" to an altitude of 8000m 
over three hours in 1875, which resulted in the death of two of the 
three balloonists (3) . 
Just as with the balloonists in "The Zenith", sudden ascent 
from sea level to the summit of Mt. Everest (8848m) may lead to 
unconsciousness and death soon thereafter (73) , yet mountaineers 
have accomplished gradual ascents over many weeks to the summit of 
Mt. Everest without the use of supplemental oxygen and without 
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adverse effects. The process by which humans adjust to the hypoxia 
of high altitude is termed acclimatization, and the primary 
physiologic mechanism in acclimatization is increased minute 
ventilation. 
Control of breathing, and ventilatory acclimatization, are 
governed at two sites: the peripheral chemoreceptors in the carotid 
body, and the central chemoreceptors in the medulla. The central 
chemoreceptors are surrounded by brain extracellular fluid and 
respond to changes in its H+ concentration. An increase in H+ 
concentrat ion stimulates ventilation while a decrease inhibits it. 
When the blood PC02 rises, C02 diffuses into the cerebrospinal 
fluid (CSF) from the cerebral blood vessels, liberating H+ ions 
that stimulate the chemoreceptors. Although the composition of the 
extracellular fluid around the receptors is primarily governed by 
the CSF, local blood flow and local metabolism also can influence 
the H+ concentration. The peripheral chemoreceptors, located in 
the carotid body at the bifurcation of the common carotid arteries, 
respond primarily to decreases in the partial pressure of arterial 
oxygen (Pa02) and, to a lesser extent, to decreases in pH and 
increases in the partial pressure of arterial carbon dioxide 
(PaC02). The peripheral chemoreceptors are responsible for all the 
increase of ventilation that occurs in man in response to arterial 
hypoxemia. The response of these receptors can be very fast, as 
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their discharge rate alters during the respiratory cycle in 
response to cyclic changes in blood gases (87). 
Increased minute ventilation during ascent to high altitude 
starts as low as 1500 m, and within the first few hours of altitude 
exposure. The increase of ventilation during acute exposure to 
high altitude is mediated through the carotid body which senses a 
decrease in Pa02. This response is termed the hypoxic ventilatory 
response (HVR) which varies among individuals and is partly 
determined genetically (86) . A high HVR may aid in acclimatization 
(68), but a blunted ventilatory response is not necessarily 
deleterious (71) , although some studies have suggested that a low 
HVR may play a role in susceptibility to AMS (63). 
Acutely, increased ventilation at high altitude leads to 
hypocapnia and a respiratory alkalemia that serve to decrease 
central respiratory drive, limiting further increases in 
ventilation. Over the ensuing hours to days at high altitude, 
however, a progressive increase in minute ventilation occurs, 
reaching a maximum after four to seven days at the same altitude 
(10). This increase in ventilation initially is achieved more by 
an increase in tidal volume than in frequency, but over time 
respiratory rate also increases. The role that the HVR plays in 
the progressive increase in ventilation observed over days of 
exposure to high altitude is unclear. Some investigators report 
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an increased HVR during acclimatization and others report no such 
change. An increase in mouth occlusion pressure (P0-1) , however, 
is consistently observed during acclimatization reflecting 
increased central respiratory drive (73). 
The classic explanation for the progressive increase in minute 
ventilation over several days is that a bicarbonate diuresis occurs 
within 24 to 48 hours after arrival at high altitude. This returns 
both blood and CSF pH towards normal, thus removing the inhibitory 
effect of alkalemia on central respiratory drive. However, 
observations of persistent alkalosis in the blood and CSF even 
after ten days at high altitude, and as minute ventilation begins 
to stabilize at a higher level, indicate that the process is more 
complex than the classic explanation suggests (18). Some 
investigators have examined other factors besides the CSF pH that 
might influence the environment of the central chemoreceptors. 
Lactate generated from the brain during hypoxia and hypocapnic 
alkalosis appears to create an acid environment in the brain's 
interstitial fluid despite an alkaline CSF. This might contribute 
to an increases central respiratory drive. Recent data, however, 
suggest that the time course of this central nervous system (CNS) 
acidosis does not correspond to the ventilatory response during 
acclimatization (73). 
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Other studies have shown that although hypoxic 
chemosensitivity does not change on exposure to high altitude, the 
hypercapnic ventilatory response (HCVR or AVE/APC02) increases 
(59) . This stimulates a greater level of minute ventilation for 
a given level of PC02 than at sea level, as the entire HCVR curve 
shifts to the left. The enhanced central responsiveness to C02 may 
be explained, at least in part, by a greater change in [H+] for a 
given level of C02 crossing the blood brain barrier due to the 
lower bicarbonate concentration in the brain intracellular fluid 
and CSF (73) . Hypocapnic hypoxia appears essential to ventilatory 
adaptation, because when individuals are exposed to isocapnic 
hypoxia for 75 hours, no change in the HCVR is seen (9) . While 
apparently a CNS phenomenon, the mechanism for this enhanced 
ventilatory response to C02 is unknown. 
The persistent alkalemia observed during acclimatization to 
high altitude suggests that the oxyhemoglobin dissociation curve 
shifts to the left. Work by Ancel Keys in the 1930's demonstrated 
a left shift in the oxyhemoglobin dissociation curve up to 4400m, 
but then a right shift was observed from 4400m up to 6100m (52). 
Keys proposed that the right shift at higher altitudes was 
advantageous because it enhanced oxygen unloading at the systemic 
tissues. This right shift of the oxyhemoglobin dissociation curve 
occurs because of increased 2,3 DPG generated during hypoxia. 
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However in more recent experiments, during a simulated ascent to 
the summit of Mt. Everest (8848m), the oxyhemoglobin dissociation 
curve was observed to shift to the left because of extreme 
hyperventilation and respiratory alkalosis (85) . This would 
facilitate oxygen loading of red blood cells (RBCs) in the lung and 
raise arterial oxygen saturation. Improved unloading of oxygen 
from RBCs at the tissues may not be beneficial unless sufficient 
saturation of hemoglobin with oxygen has occurred during passage 
through the lungs. Thus a left shift of the oxyhemoglobin 
dissociation curve may be more advantageous at extreme altitudes. 
A more long term physiologic adaptation to altitude is an increase 
in erythropoietin leading to increased marrow production of red 
blood cells and an enhanced oxygen carrying capacity (79). 
For the circulatory system, ascent to high altitude increases 
catecholamine levels leading to peripheral vasoconstriction and a 
mild increase in both systolic and diastolic blood pressures. 
Heart rate, cardiac output, and venous tone are modestly elevated. 
Resting heart rate returns to near sea level values with 
acclimatization, except at extreme altitude. Maximum heart rate 
is limited by maximal oxygen uptake - which declines with 
increasing altitude. This occurs because cardiac output is not a 
limiting factor for performance at high altitude. Instead the 
decreased oxygen delivery to the tissues limits the work performed. 
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During a simulated ascent to a barometric pressure equal to that 
at the summit of Mt. Everest, cardiac function was equivalent to 
values obtained for the same level of work performed as at sea 
level (65) . 
The pulmonary circulation responds to the global hypoxia at 
high altitude with pulmonary vasoconstriction. This results in 
elevated pulmonary artery pressure that increases further with the 
high cardiac output of exercise. Pulmonary hypertension at high 
altitude is not completely reversible with oxygen administration, 
which suggests that the increased pulmonary vascular resistance at 
altitude may not be due solely to hypoxic pulmonary 
vasoconstriction (22,48). Some individuals with a history of HAPE 
are particularly susceptible to pulmonary hypertension at altitude 
(48). Still, even with mean pulmonary artery pressures up to 60 
torr, cardiac output remains appropriate and right atrial pressures 
do not rise above sea level values, suggesting that right 
ventricular function remains intact (22). This is an interesting 
contrast to the patient with respiratory failure at sea level. 
The mechanisms of acclimatization discussed so far may begin 
as low as 1500m, and continue to occur with ascent to progressively 
higher altitudes. The degree of arterial hypoxemia and resulting 
physiological responses, however, vary according to the eventual 
altitude reached. At 1500m the barometric pressure of 630 torr 
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results in a partial pressure of inspired oxygen (Pi02) of 122 
torr, a Pa02 of 80 torr, and a PaC02 of 33 torr. On the summit of 
one of the 14 peaks in the world over 8000m the barometric pressure 
is less than 280 torr, the Pi02 less than 50 torr, the Pa02 
approximately 35 torr, and the PaC02 approximately 13 torr (35). 
Clearly, the same degree of acclimatization is not required to 
travel to Denver, Colorado, at just over 1500m, as is required to 
climb an 8000m peak in the Himalaya. Therefore, Hackett defined 
three different ranges of altitude that elicit a progression of 
physiological responses and may result in differing severities of 
altitude illness: high altitude (1500m to 3500m), very high 
altitude (3500m to 5500m) , and extreme altitude (over 5500m) (35) . 
At high altitude, 1500m to 3500m, the onset of physiologic 
effects of diminished Pi02 include decreased exercise performance 
and increased ventilation at rest. Arterial oxygen saturation at 
rest remains above 90%. Still, AMS is common with one or two day 
ascents from sea level to over 2500m. At very high altitude, 3500m 
to 5500m, arterial oxygen saturation at rest falls to less than 90% 
as the Pa02 falls to or below 60 torr. Extreme hypoxemia may occur 
during exercise, sleep, and altitude illness. This is the most 
common range for serious altitude illness. At extreme altitude, 
over 5500m, marked hypoxemia and hypocapnia occur as the Pi02 falls 
even further and ventilation continues to increase. This range is 
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above the highest permanent human habitat 
altitudes, acclimatization does not 
deterioration of physiologic function (35). 
ion because, at these 
prevent progressive 
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III. HIGH ALTITUDE ILLNESS: HAPE AND HACE 
Almost all individuals physiologically acclimatize to high 
altitude given sufficient time, but only some individuals 
experience one of the spectrum of high altitude syndromes. These 
include but are not limited to: acute hypoxia, disordered sleep, 
sleep periodic breathing, AMS, HAPE, and HACE. Other high altitude 
illnesses that will not be discussed here include thromboembolic 
problems, cerebrovascular syndromes, and high altitude retinopathy 
(35) . 
■It can be difficult at times to clearly separate high altitude 
illnesses, as considerable overlap may exist in their presentation 
and progression. An individual may present with symptoms 
consistent with AMS and then go on to develop HAPE or HACE. 
Likewise, disordered sleep or sleep periodic breathing frequently 
occur without clinically defined AMS, or a sleep disturbance may 
be part of the symptom complex of AMS. An understanding of some 
of the more important high altitude syndromes is therefore 
important, as it provides a background from which to evaluate the 
presentation and follow the progression of AMS. 
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High Altitude Pulmonary Edema: 
HAPE is a form of noncardiogenic pulmonary edema that occurs 
predominately in young healthy individuals without underlying 
pulmonary or cardiac disease after acute ascent to high altitude 
(70) . The incidence varies with the ultimate altitude attained 
and with the rate of ascent. The incidence has been reported as 
high as 15% in Indian troops airlifted from sea level to altitudes 
between 3500m and 5500m (76), 1-2% in climbers during ascents of 
Mt. McKinley, Alaska at elevations up to 6150m (69), .01% in male 
visitors to Vail, Colorado at an elevation of 2500m (77). The 
clinical presentation consists of fatigue, dyspnea at rest, marked 
decrease in exercise tolerance, and a dry cough that becomes 
productive of white frothy sputum over 24 to 48 hours (70) . 
The definitive treatment for HAPE is descent, with symptoms 
most often resolving within 24 to 48 hours (70) . Even a modest 
decent of 500m to 1000m may lead to improvement (69). If descent 
is not undertaken death may follow within days of the onset. In 
some situations, however, descent may not be a viable option, as 
with climbers or trekkers caught in adverse weather conditions in 
difficult terrain. In these situations supplemental oxygen is 
helpful, if available. Another alternative, that does not require 
the bulk and weight of bottled oxygen, is a continuous positive 
airway pressure (CPAP) mask. The CPAP mask is effective in 
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improving ventilation - perfusion mismatch and oxygenation in HAPE 
(74), similar to the use of positive airway pressure in other forms 
of diffuse pulmonary edema with hypoxemia. Still, the CPAP mask 
should be used only as a temporizing measure until evacuation or 
descent is undertaken. 
Beginning with the first description of HAPE by Charles 
Houston in 1960 (45), and subsequent work by Hultgren clearly 
showing that HAPE is a form of noncardiogenic pulmonary edema 
occurring after ascent to high altitude (48), the etiology of HAPE 
has been debated. High pulmonary artery pressures at altitude 
observed in individuals with a history of HAPE led to speculation 
that HAPE results from overperfusion of a constricted pulmonary 
vascular bed with a resulting transudative leak (48). An 
"experiment of nature" supported this theory when Hackett reported 
four cases of HAPE at moderate altitude in four individuals with 
congenital absence of the right pulmonary artery (27). Schoene, 
however, performed fiberoptic bronchoscopy and bronchoalveolar 
lavage on individuals with HAPE and controls at 4200m on Mt. 
McKinley, and found high concentrations of protein and cells in the 
lavage fluid from the HAPE subjects, indicating increased capillary 
permeability and an inflammatory component (72) . Although the 
exact mechanism leading to transvascular protein and fluid flux in 
HAPE is still unknown, it appears that both pulmonary hypertension 
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and a compromise in the pulmonary vascular endothelium play roles 
in the pathogenesis. It is also notable that a few authors 
postulate that an element of neurogenic pulmonary edema may 
contribute to this process (40), perhaps by augmenting pulmonary 
vascular resistance and increasing central blood flow. 
High Altitude Cerebral Edema: 
HACE is characterized by progression of global cerebral signs 
and symptoms in the setting of AMS, and may occur with HAPE. 
Common features include truncal ataxia, severe headache, vomiting, 
impaired motor and sensory functions, hypo- or hyperreflexia, 
papilledema, and altered level of consciousness. Less common 
features include hallucinations, scotoma, visual field defects, 
pupillary changes, blurred vision, speech difficulty, cranial nerve 
palsies, rigidity or flaccidity, tremor, hemiparesis, convulsions, 
obtundation, stupor, and coma (35,40). The most common clinical 
presentation, however, is change in consciousness associated with 
ataxia, without focal neurological signs (35,76). The progression 
from mild AMS to unconsciousness may be as fast as 12 hours, but 
usually requires 1-3 days (35). The preferred treatment for HACE 
is descent, although symptoms may not resolve quickly as with HAPE. 
Supplemental oxygen, if available, is probably useful but should 
not substitute for descent. Anecdotal reports suggest that 

17 
dexamethasone also may be useful in treatment, with therapy earlier 
in the illness producing better results (40) . 
Gross cerebral edema in HACE has been documented on CT scans 
(54), as well as on necropsy (11,12). Pathological features of 
HACE seen at autopsy include edema of the white matter, widespread 
petechial hemorrhages, and sludging of erythrocytes in capillaries 
(40) . Elevated CSF pressures of up to 210 mm H20 also are seen 
(76) . At present, two pathophysiological theories are proposed to 
explain the brain edema seen in HACE. One view suggests that high 
altitude brain swelling is caused by a cerebral vasodilatory 
response to hypoxia with subsequent increased cerebral blood flow. 
Moderate cerebral hypertension and strenuous exercise then 
overwhelm the integrity of the blood - brain barrier, leading to 
transcapillary and transarteriolar leakage, and a vasogenic, 
multifocal cerebral edema ensues. This contrasts sharply with the 
view that HACE is caused by massive hypoxic cell damage leading to 
cytotoxic edema. In this theory, failure of the sodium pump, Na+ - 
K+ ATPase, at the cell membrane would lead to accumulation of Na + 
and water within cells, resulting in cell death (16). If this 
process occurred in the cerebral endothelial cells, a superimposed 
vasogenic edema also would occur (40). Steroids may be beneficial 
in the treatment of vasogenic cerebral edema, but not other kinds 
of cerebral edema (40) . Reports of the successful treatment of 
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HACE with dexamethasone suggest that vasogenic edema, 
primary or secondary to cytotoxic edema, plays a role 
pathophysiology of HACE. 
whether 
in the 
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IV. AMS: DIAGNOSIS, PATHOPHYSIOLOGY, AND NATURAL HISTORY 
AMS is a symptom complex commonly seen in individuals from 
six to 96 hours after ascending to altitudes above 2500m 
(30,31,76). Most individuals with AMS present with a milder form, 
characterized by headache, anorexia, nausea, vomiting, oliguria, 
and malaise. The more severe form of AMS presages HAPE or HACE and 
can be characterized by an altered level of consciousness, ataxia, 
rales, cyanosis, and dyspnea at rest (31,35) . Although the 
symptoms and severity of AMS vary, AMS is characterized by greater 
severity with more rapid ascent to higher altitudes. For persons 
who are partially acclimatized, abrupt ascent to a higher altitude, 
overexertion, and use of respiratory depressants are common 
contributing factors (35). 
The most effective prophylaxis for AMS is slow ascent. Most 
people, however, exceed the ascent rates recommended for 
prophylaxis and thus increase their susceptibility to AMS. The 
incidence is as high as 67% in climbers making a rapid ascent (33 
hours) to 4392m on Mt. Ranier (57), 31% in trekkers walking from 
Kathmandu (1300m) to Pheriche (4243m) (30), and 12% in skiers going 
from Denver (1600m) to resorts in the Colorado Rockies at 2400m to 
2800m (46). 
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Diagnosis of AMS: 
The diagnosis of AMS is based on the symptoms and physical 
findings in the setting of acute ascent to high altitude. To 
diagnose AMS, it is not necessary that an individual exhibit all 
the common symptoms seen in the milder form, as symptoms and 
severity of AMS vary widely among persons. Symptoms of AMS, 
however, usually are consistent in a given individual from one 
altitude exposure to the next (76) . In clinical research a 
symptom score is used to diagnose AMS (25,14), rather than a 
specific constellation of symptoms. A symptom score diagnostic of 
AMS would require only that a certain number of symptoms be 
present, or that a given severity of one symptom is observed. 
The most common symptoms of AMS are headache, malaise, 
anorexia, and nausea (31). The headache is throbbing, bilateral, 
frontal, and is worse at night or in the morning after awakening. 
The latter may be due to arterial oxygen desaturation observed 
during sleep at high altitude (80) . Sleep may be fragmented by 
frequent awakenings caused by periodic breathing during sleep at 
high altitude, but this is common in all individuals above 2800m 
and does not constitute an absolute diagnostic symptom (80,37). 
Lassitude can be disabling, causing loss of interest in activities 
of daily living, and sometimes requiring the care of others. 
Pulmonary symptoms vary considerably. Dyspnea on exertion at high 
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altitude is common, and occurs in virtually all persons at extreme 
altitude. At more moderate altitudes it may be difficult to 
determine when dyspnea on exertion is of an abnormal degree. 
Dyspnea on exertion forcing frequent stops or dyspnea at rest, 
however, are distinctly abnormal and suggest the development of 
HAPE (707). 
Just as with symptoms, specific physical findings diagnostic 
of mild AMS are not present in every case. Some authors describe 
tachycardia, while others note a mild bradycardia in AMS (76). A 
25% - 35% incidence of rales localized to one side of the chest is 
present in AMS (31,76). Fluid retention causes peripheral edema 
and weight gain, and contrasts with the normal diuresis at altitude 
(31,76). As AMS progresses, physical findings become more 
prominent with ataxia being the single most useful sign of 
progression from mild to severe (35). Lassitude and mental status 
changes may also become more severe. 
Pathophysiology of AMS: 
Although hypobaric hypoxia is the initial insult leading to 
AMS, the onset of AMS is delayed after initial exposure to high 
altitude, and the administration of oxygen does not completely 
relieve symptoms (35) . This contrasts with the consequences of 
acute hypoxia, which occur immediately after an abrupt hypoxic 
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insult and are due directly to the effects of hypoxia. The 
symptoms of acute hypoxia are primarily due to cerebral hypoxia 
and are readily relieved by oxygen inhalation (35,76). 
The delay in onset of AMS after ascent to high altitude 
suggests that it is the body's response to hypoxia, rather than 
the direct effects of hypoxia itself, that determines the character 
of the illness. These pathophysiologic responses to hypoxia in AMS 
include: relative hypoventilation (29,63); fluid retention and 
antidiuresis (29,31); shift of fluid from the extracellular to the 
intracellular space (41); increased CSF pressure (76); impaired 
pulmonary gas exchange (78); and decreased forced vital capacity 
(1) . 
Relative hypoventilation is seen in AMS and may be due to a 
low HVR, or ventilatory depression associated with AMS . It is 
unclear whether a low HVR measured at sea level correlates with 
susceptibility to AMS. Some investigators have found an 
association between low HVR values and susceptibility to AMS (63) . 
Other studies show no correlation between the HVR measured at sea 
level and the severity of AMS on ascent to altitude (78) . In 
individuals with established cases of AMS, however, lower alveolar 
ventilation and a higher PaC02 are observed as compared to healthy 
individuals at the same altitude (29,78). Furthermore individuals 
susceptible to AMS show a greater blunting of ventilation in 
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response to respiratory alkalosis at high altitude (63). A very 
low HVR measured before ascent to altitude may indicate 
susceptibility to AMS, but for the majority of individuals with 
intermediate HVR values, ventilatory drive probably has no 
predictive value (35). The relative hypoventilation seen in AMS, 
then, may be primarily due to ventilatory depression associated 
with the CNS effects in AMS. 
Antidiuresis, peripheral edema, and weight gain occur early 
in the development of AMS (29,31,76), whereas those individuals 
who remain healthy on ascent to high altitude diurese one to five 
liter-s (76). Relative hypoventilation (the absence of hypocapnia) 
is associated with water retention and weight gain in AMS (29) , 
although the mechanism for this relationship is unclear. Possible 
mechanisms contributing to fluid retention in AMS include: 
increased antidiuretic hormone (ADH); abnormalities in the renin - 
aldosterone axis; and intracellular fluid shifts. A study by 
Hackett and colleagues demonstrated increased blood ADH levels in 
individuals with AMS (28) . It could not be discerned, however, 
whether increased ADH is a primary abnormality that is a major 
factor in the pathophysiology of AMS, or followed as a result of 
AMS. Increased ADH secretion could be an appropriate secondary 
response to intravascular volume depletion from fluid shifts out 
of the vascular bed, or simply a direct result of stress. Nausea, 

a common symptom in AMS, also stimulates ADH release (44). Other 
studies have failed to show changes in blood ADH levels, or urinary 
ADH excretion, at high altitude (44). 
Some investigators have examined the renin-aldosterone axis 
during ascent to high altitude. At rest, hypoxia results in 
decreased plasma renin activity (PRA) (4,44). Although exercise 
at sea level results in increased PRA, studies measuring PRA during 
exercise at high altitude have shown conflicting results. One 
study demonstrated significantly lower levels of PRA during 
exercise at high altitude that were not related to beta 
adrenergic activity (4) , while other studies have demonstrated 
increased PRA during exercise at high altitude (44) . Plasma 
aldosterone levels, however, are depressed both at rest and during 
exercise at high altitude (4,44). It is tempting to speculate that 
those individuals susceptible to AMS do not suppress aldosterone 
secretion to the same degree as individuals who remain healthy at 
high altitude. Measured aldosterone levels in individuals with 
AMS, however, have been surprisingly low (44), and thus cannot 
explain fluid retention. Interestingly, in a double blind placebo 
- controlled study, spironolactone was shown to be partially 
effective in preventing AMS (56) . Angiotensin converting enzyme 
(ACE) also is reduced during hypoxia, and those individuals 
susceptible to AMS show less of a reduction in ACE levels as 
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compared to healthy individuals (60). Some studies of the renin - 
angiotensin system, however, have shown no consistent changes 
(35). The role of atrial natriuretic factor in the development of 
AMS has not been well studied. 
With ascent to altitude, a shift of fluid from the 
extracellular and interstitial compartments to the intracellular 
space is well established, and can be as much as three liters in 
volume (41) . A possible mechanism for the intracellular fluid shift 
might be failure of the sodium pump, Na+ - K+ ATPase, resulting in 
intracellular sodium retention and consequent water accumulation 
(16) . These fluid shifts may increase brain tissue water and 
contribute to the CNS symptoms in AMS and progression to HACE (42) . 
Increased intracranial pressure has been observed in more 
advanced cases of AMS (76), suggesting a similar pathophysiology 
as discussed for HACE. Cellular swelling due to hypoxic injury, 
or vasogenic edema from increased permeability of the blood brain 
barrier, may cause the increased intracranial pressure in both AMS 
and HACE (40). The fact that dexamethasone improves AMS (14,50) 
and possibly also vasogenic cerebral edema, but not other types of 
cerebral edema, suggests that vasogenic edema may be a mechanism 
in AMS (35). 
The etiology of headache in AMS is unclear, and may be due to 
increased intracranial pressure, increased cerebral blood flow, or 
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cerebral vasoconstriction - similar to a migraine episode. Hypoxia 
and hypercapnia dilate, while hypocapnia constricts the cerebral 
blood vessels (49). Some authors speculate that the hypocapnic 
hypoxia of altitude favors cerebral vasodilation, and may be 
responsible for the headache in AMS (49) . The relative 
hypoventilation in AMS leads to higher PaC02 and lower Pa02 values 
(29) that would tend to cause cerebral vasodilation. Studies 
measuring cerebral blood flow at high altitude have shown 
conflicting results; some studies reveal increased cerebral blood 
flow (2) and others show no change (39) . Studies using C02 
rebreathing to relieve high altitude headache also have had 
conflicting results. A recent study by Harvey and colleagues 
indicates that breathing a 3% C02 mixture in ambient air at high 
altitude relieved the headache in AMS (43), and the authors 
speculate that this is due both to increased oxygen delivery to the 
brain and to cerebral vasodilation. Hackett points out that relief 
of headache in this study could have been due to increases in Pa02 
observed in the subjects, rather than to any effect of cerebral 
blood flow (23) . In the only study where subjects with AMS 
breathed an added C02 mixture and had alveolar oxygen tension 
maintained at the same level as controls, the headache in AMS was 
not relieved (58). Based on experience treating individuals with 
AMS at 4200m on Mt. McKinley, Hackett and colleagues claim that 
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oxygen, but not increased cerebral blood flow, improves high 
altitude headache (23). 
The clinical presentation in AMS is consistent with cerebral 
dysfunction, but pulmonary dysfunction also occurs. A decreased 
forced vital capacity and peak expiratory flow rate (1,76,57), and 
a 25% to 35% incidence of rales are observed in AMS (31,76) . 
Impaired pulmonary gas exchange as evidenced by an increased 
alveolar to arterial oxygen pressure difference (A-a oxygen 
gradient or (A-a)D02) is also seen in AMS, indicating a greater 
degree of hypoxemia for a given level of ventilation. Sutton and 
colleagues showed that an increasing (A-a)D02 on exposure to 5360 
m correlated with more severe symptoms of AMS (78), while Hackett 
found that individuals at 4200m with moderate AMS had an (A-a)D02 
of approximately 16 torr as compared to an (A-a)D02 of 
approximately 7 torr in healthy individuals (38). These findings 
are consistent with increased extravascular lung water in AMS, 
leading to interstitial and perivascular pulmonary edema. 
Reeves found that (A-a)D02 increased in seven subjects from 
6 torr at sea level to 12 torr after acute exposure to 425 torr in 
a hypobaric chamber (66). In a more recent study subjects were 
gradually acclimatized to extreme altitude (4500m to 8800m) in a 
• • 
hypobaric chamber. Marked ventilation perfusion (VA/Q) mismatching 
was observed with both exercise and acute increases in altitude. 
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and correlated with the level of pulmonary artery pressure. The 
• • 
pattern of development of VA/Q mismatch in this study, 
• • 
characterized by areas of shunt or very low VA/Q ratio, and the 
correlation with pulmonary artery pressure, suggested to the 
authors that pulmonary interstitial edema occurs in individuals 
without clinical evidence of HAPE at extreme altitude (85) . 
The low grade pulmonary edema that may occur in AMS appears 
to be distinct from HAPE. Schoene performed bronchoalveolar lavage 
on four individuals with AMS at 4200m on Mt. McKinley (72) . 
Despite gas exchange abnormalities in AMS, the bronchoalveolar 
lavage fluid from subjects with AMS showed no evidence of abnormal 
protein or cell concentrations. This contrasts with HAPE where 
large concentrations of proteins and cells are seen in the 
bronchoalveolar lavage fluid. 
The coexistence of pulmonary dysfunction and cerebral 
dysfunction in AMS raises the question of cause and effect. 
Impaired pulmonary gas exchange leads to a greater degree of 
hypoxemia for a given level of ventilation, and thus a greater 
degree of cerebral hypoxia. Some authors have speculated, however, 
that there may be a neurogenic component to the pulmonary edema at 
high altitude (13). Thus pulmonary dysfunction and cerebral 
dysfunction may each compound the other, but which comes first is 
still an unanswered question (24). 
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Natural History of AMS: 
The natural course of AMS exhibits considerable individual 
variation. Singh (76) studied men, 18 to 53 years old, who were 
transported by ground or air from sea level to elevations of 3300m 
to 5500m as part of Indian military exercises. Symptoms began 
between six and 96 hours after arrival at high altitude. No 
correlation between the severity of illness and increasing altitude 
was found, but illness was aggravated by colder weather and 
physical activity. Symptoms were worse after air travel and 
correlated with time of ascent during road travel. Also, 
individuals with a prior history of AMS were more likely to 
experience symptoms after ascent to altitude. In 840 untreated 
individuals experiencing AMS, the duration of incapacitating 
illness varied from two to five days. During their prolonged stay 
at altitude, 38% were symptom free within three days, another 21% 
were symptom free within four to seven days, and another 25% were 
symptom free within eight to 21 days. The remaining approximately 
15% required up to five months to become symptom free, with 1% 
(nine individuals) failing to acclimatize within six months. 
Hackett studied 278 trekkers passing through 4243m in the 
Himalayas of Nepal (30), and also found unpredictable individual 
variation in the natural course of AMS. The overall incidence of 
AMS was 53%. AMS occurred more frequently in the young, in those 
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who flew to 2800m before trekking to 4243m, and in those who spent 
fewer nights acclimatizing en route. The severity of AMS was 
inversely related to age and the highest altitude attained, and was 
highly correlated with speed of ascent. Out of 146 individuals 
experiencing AMS, 63% were able to continue their ascent, dosing 
themselves with mild analgesics and sleeping pills for headache and 
insomnia. The remaining 37% had to stop ascending for two to three 
days to obtain relief of symptoms, or more often, had to descend 
and reascend later. Some (8.2%) required intensive medical therapy 
and evacuation because of the development of pulmonary and/or 
cerebral edema. 
At the more intermediate altitudes of the ski resorts in the 
Rocky Mountains (2000 - 2500m) the natural history of AMS appears 
to be milder, although this has not been well studied. Montgomery 
reported that among 454 individuals travelling to Park City, Utah 
(2090m), or Steamboat Springs, Colorado (2100m), for week long 
medical meetings, 90% of AMS symptoms resolved within 72 hours of 
onset (61) . 
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V. AMS: PREVENTION AND TREATMENT 
Prevention of AMS: 
Clearly the best prevention for AMS is a gradual ascent. If 
symptoms occur, descent is recommended early in the course of the 
illness to prevent progression. This is especially important in 
more isolated mountainous terrain where progression of AMS to a 
more severe form, or to HAPE or HACE, could require medical 
attention in a situation where rescue can be both difficult and 
dangerous. A common method used by mountaineers at high altitude 
to prevent AMS and aid acclimatization is to climb at higher 
altitudes and sleep at lower altitudes, moving the sleeping 
altitude up every few days. For individuals trekking at less 
extreme altitudes, sleeping two nights at the same altitude for 
every 600m gained above 3000m will achieve the same result. 
Proceeding to a higher sleeping altitude in the presence of 
symptoms is contraindicated (35). 
Acetazolamide, a potent carbonic anhydrase (CA) inhibitor, is 
beneficial in the prophylaxis of AMS, decreasing both its incidence 
and severity (30,57,8). Inhibition of renal CA results in a 
bicarbonate diuresis and the generation of a metabolic acidosis. 
This increases inspiratory minute ventilation due to an increased 
hypercapnic ventilatory response (84,51). In individuals ascending 
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to high altitude, acetazolamide increases resting minute 
ventilation (57), decreases PaC02, and increases Pa02 (8,51). 
Perhaps quite importantly, acetazolamide also decreases periodic 
breathing and increases arterial oxygen saturation during sleep at 
high altitude (37,80) . Because of its diuretic action, 
acetazolamide may counteract the fluid retention that occurs in AMS 
(35) . Acetazolamide also diminishes CSF production and volume, and 
possibly CSF pressure (75). 
The effects of acetazolamide on CA are complex because of 
different isoenzymes of the enzyme. This causes a complex response 
to different doses of the drug; low doses of acetazolamide inhibit 
only renal CA, while higher doses inhibit both renal and RBC CA 
(7) . The RBC contains both more CA isoenzyme II (the main renal 
and RBC enzyme) and contains an isoenzyme not found in the kidney 
that is ten fold less sensitive to inhibition by acetazolamide 
(81) . Acetazolamide doses of less than 5 mg/kg produce no 
respiratory effect, but a marked renal effect (7). 
Inhibition of renal CA results in a metabolic acidosis due to 
the renal loss of bicarbonate. Inhibition of RBC CA results 
initially in carbon dioxide retention and a respiratory acidosis. 
This occurs because C02 does not completely equilibrate during its 
transit through the pulmonary capillary bed. Also, in the tissues 
inhibition of RBC CA reduces the fraction of metabolically produced 
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C02 that can be converted to HC03- and carried in the RBC or plasma 
to the lungs. In order to effectively eliminate C02 in the lungs, 
a gradient is created with a high C02 in the tissues and venous 
circulation to a lower C02 in the lungs. The ensuing respiratory 
acidosis, particularly in the tissues of the CNS, increases minute 
ventilation. In normal individuals, both the metabolic acidosis 
caused by renal CA inhibition and the respiratory acidosis caused 
by RBC CA inhibition increase ventilation, improve Pa02, and 
decrease PaC02. In individuals with lung disease or defects in 
ventilatory control, however, if minute ventilation does not 
increase in response to the respiratory acidosis caused by 
inhibition of RBC CA, an increase in PaC02 and a further drop in 
pH will result (81). Relative hypoventilation occurs in AMS (29) 
and a blunted ventilatory drive occurs in HAPE (70) . Therefore, 
inhibition of RBC CA in individuals with AMS or HAPE may not be 
advantageous. 
Benzolamide, a preferential renal CA inhibitor, prevents AMS 
and eliminates sleep periodic breathing at high altitude, but was 
found to be no better than acetazolamide for AMS prophylaxis 
(51,82). Still, Swenson suggests that low doses of acetazolamide 
(5 mg/kg), inhibiting only renal CA, may be most appropriate for 
prevention of both AMS and sleep periodic breathing at high 
altitude (81) . Benzolamide might be ideal for this purpose, but 
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is not commercially available. 
In an early study Cain used acetazolamide given as a one time 
dose of 750 mg and found that it was effective in preventing AMS 
during acute exposure to 4270m (8). Larson and colleagues used 
acetazolamide 250 mg every eight hours beginning one day before 
ascent in a study of climbers making a rapid ascent of Mt. Rainier 
(4394m) and demonstrated effective prophylaxis of AMS (57) . 
Hackett suggests the use of low doses (125 to 250 mg) of 
acetazolamide twice daily beginning 24 hours before ascent to aid 
acclimatization and prevent AMS (35). Most authors recommend 
continuing acetazolamide for the first day or two at altitude, and 
then discontinuing the drug once acclimatization is established and 
the danger of AMS is passed. The 500 mg sustained release capsule 
taken once daily may be ideal for AMS prophylaxis. Once at 
altitude a dose as low as 125 mg every evening will result in less 
side effects and may still prevent sleep periodic breathing (34). 
Dexamethasone, a potent synthetic glucocorticoid with 
negligible mineralocorticoid activity, also is effective in the 
prophylaxis of AMS in both passive and rapid active ascent to high 
altitude (14,50,67). Ellsworth demonstrated effective prophylaxis 
of AMS during rapid active ascent of Mt. Ranier (4394m) using 4 mg 
of dexamethasone every eight hours beginning 24 hours before ascent 
(14). Rock studied individuals exposed to a simulated altitude of 
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4570m in a hypobaric chamber for 45 hours and determined that 4 mg 
of dexamethasone every 12 hours, but not 1 mg every 12 hours, was 
effective in preventing AMS (67) . Dexamethasone did not alter 
fluid balance or plasma volume, but did suppress cortisol 
secretion. Dexamethasone 2 mg every six hours beginning one hour 
prior to air transport from sea level to 4200m was not effective 
in preventing AMS in military personnel who were physically active 
after arrival at altitude (25). Therefore, it appears that 4 mg 
every 12 hours is the minimum dose of dexamethasone effective in 
the prevention of AMS. Although dexamethasone may be as effective 
as acetazolamide in preventing AMS (14), most authors warn that 
because of the potential toxic effects of dexamethasone its use 
should be reserved for treatment of severe AMS, or for prophylaxis 
in individuals allergic to acetazolamide (35,14). 
Treatment of AMS: 
The most effective treacment for AMS is descent to an altitude 
below that where the first symptoms of AMS were experienced. 
Still, it is clear that in many individuals symptoms will resolve 
after halting ascent and waiting for acclimatization to improve, 
which may take several days or longer (30,76). Proceeding to a 
higher altitude in the presence of symptoms is contraindicated as 
it may lead to HAPE or HACE, and immediate descent should be 
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undertaken if there is any evidence of an abnormal neurological 
examination (ataxia or changes in consciousness) or with evidence 
of pulmonary edema (35). In some situations, however, descent may 
not be an option because of adverse weather conditions encountered 
by both climbers and trekkers in the high mountain ranges of the 
world. Therefore, effective pharmacological treatment for AMS has 
been sought. 
Oxygen, if available, is effective in relieving the symptoms 
of AMS. In addition to increasing Pa02, oxygen also lowers 
pulmonary artery pressure (48) and reduces cerebral blood flow 
(36,23). Oxygen is particularly effective in improving 
disordered sleep in AMS, and may be given at low flow rates (1- 
2L/min) during the night. Oxygen many times, but not always, 
relieves the headache associated with AMS (35). Still, most 
experienced mountain doctors and lay mountaineers have consistently 
observed that descent is more effective than oxygen in the 
treatment of AMS (24). Also, when oxygen therapy is discontinued, 
symptoms of AMS return. When combined with the bulk and expense 
of carrying supplemental oxygen, this provides further motivation 
for finding effective pharmacological treatment. 
Symptomatic therapy for AMS includes analgesics such as 
aspirin and acetaminophen (35) . Aspirin is useful in reducing 
headache and promoting sleep, but is not effective for treating 
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other symptoms of AMS (76). Prochlorperazine (compazine) can be 
given for the nausea and vomiting and has the advantage of 
augmenting the HVR (64). Other antiemetics may depress the HVR. 
Persons with AMS should avoid alcohol and sedative hypnotics near 
bedtime because of the danger of respiratory depression during 
sleep (35) . Short-acting, short half-life, benzodiazepines are 
probably safe to use (34), but if insomnia is primarily due to 
periodic breathing the respiratory stimulant acetazolamide is 
superior (37,80). Almitrine, used to increase Sa02% during sleep 
at sea level in patients with COPD, also improves Sa02% during 
sleep at high altitude, but increases periodic breathing 
apparently by increasing the HVR (37). 
The respiratory alkalosis at high altitude serves to decrease 
central respiratory drive and, at least theoretically, an agent 
that normalizes the blood pH at high altitude might be useful in 
treating AMS. However, Singh gave ammonium chloride orally, in a 
dose of 2 gm three times a day for three days, to 30 patients with 
AMS and found that it resulted in no improvement in symptoms. In 
fact, 23 patients felt worse after ammonium chloride therapy (76). 
This is surprising because one of the presumed mechanisms for the 
increase in central ventilatory drive seen with acetazolamide is 
the generation of a metabolic acidosis. 
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Adding C02 to inhaled air also has been used for the treatment 
of AMS. In a recent study, Harvey and colleagues found that 
breathing a 3% C02 mixture in ambient air at altitudes between 
3400m and 5400m relieved the symptoms of AMS, increased Pa02, and 
decreased blood pH (43). The clinical benefit lasted for 30 to 60 
minutes after inhalation of C02, but symptoms returned on breathing 
of ambient air. 
Dexamethasone is effective in the treatment of AMS after both 
passive and active ascent to high altitude (15,25,55). Ferrazzini 
used an 8 mg dose initially and then 4 mg every six hours in 17 
individuals with AMS at 4459m in the Alps. Dexamethasone relieved 
symptoms, improved arterial oxygen saturation, and slightly, but 
significantly, improved forced vital capacity (FVC) and forced 
expiratory volume in one second (FEVj) as compared to placebo (15). 
Hackett treated 11 individuals with AMS after air transport from 
sea level to 4400 m on Mt. McKinley with a 4 mg dose of 
dexamethasone, given IM or PO, and noted relief of symptoms in 24 
hours. Dexamethasone was discontinued after 24 hours and five of 
11 developed symptoms again (25,33). Levine and colleagues 
conducted a double blind, placebo - controlled, crossover trial 
using dexamethasone in the treatment of AMS after ascent to 3700m 
in a hypobaric chamber by six subjects (55) . Dexamethasone 
relieved the symptoms of AMS, but in spite of this, one subject had 

mild cerebral edema on brain CT after both placebo and 
dexamethasone. Dexamethasone had no effect on oxygenation, sleep 
apnea, urinary catecholamine levels, the appearance of chest 
radiographs or perfusion scans, serum electrolyte levels, 
intravascular volume, hematologic profiles, or the results of 
psychometric tests. All authors agree that because of the 
potential side effects of dexamethasone, and the question of 
whether it improves pathophysiologic changes occurring in AMS at 
high altitude, its use should be reserved for situations in which 
descent is impossible or in conjunction with descent to facilitate 
a patient's cooperation with evacuation efforts. 
Fluid retention in AMS provides a rationale for treatment with 
diuretics. Singh and colleagues found that furosemide, 80 mg every 
twelve hours for two days, effectively prevented AMS in Indian 
military personnel airlifted from sea level to 3500m, and decreased 
dyspnea in the treated group. They also used furosemide for the 
treatment of AMS with successful results (76). In the only other 
study, furosemide, 40 mg twice a day, was given to five subjects 
airlifted to 5400m on Mt. Logan, in Canada. All five subjects 
developed severe AMS and the authors, Gray and colleagues, 
speculated on the possible deleterious role of dehydration (21) . 
The contrast in results between these two studies is striking, and 
might be explained by the different environments. Both studies 
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used military personnel airlifted from low altitude to high 
altitude, but the environment was very different in the two 
studies. First, the altitude was higher in the North American 
study than in the Himalayan study; 5400m as compared to 3500m. More 
important, though, Singh conducted his studies at Indian military 
bases below the glacier level in the Himalaya, while Gray's study 
took place at a research camp high on a glacial plateau on Mt. 
Logan. The stresses of daily life are much greater living on a 
glacier; snow must be melted for water, tents are used for 
sleeping, and temperatures are colder. These factors increase 
required physical activity and the potential for dehydration. 
Gray's study more closely resembled situations encountered by 
climbers at high altitude, and has discouraged subsequent use of 
furosemide in North America. Still, furosemide might be helpful 
in treating severe AMS or HAPE in more controlled situations and 
warrants further study. 

VI. ACETAZOLAMIDE IN THE TREATMENT OF AMS 
VI.A. BACKGROUND 
Acetazolamide has been used for the treatment of AMS, but only 
one controlled clinical study supports this practice. Bradwell and 
colleagues studied 12 individuals with AMS during a ten day ascent 
to 5400m in a double blind, placebo controlled, design that is 
published only in abstract form (5) . Subjects were randomly 
assigned to receive acetazolamide 1500 mg in a single dose or 
placebo, and were stratified according to previous altitude 
performance. The authors did not define in the abstract how they 
diagnosed AMS. Five subjects were randomized to the acetazolamide 
group and three showed improvement in symptoms in one to six hours, 
the other two showed improvement in symptoms in 24 hours. Of the 
seven subjects randomized to the placebo group, two showed 
improvement in symptoms and five were worse overnight. After 24 
hours the placebo group crossed over to acetazolamide, with four 
subjects receiving a single dose of 1500 mg and three subjects a 
single dose of 250 mg. Six out of seven subjects in the crossover 
study improved in one to eight hours and one remained unchanged 
(the authors did not distinguish between higher and lower dose 
acetazolamide in the crossover study) . Arterialized ear lobe 
capillary P02 levels were increased in the acetazolamide - treated 
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subjects, including crossovers, as compared to controls. 
Interestingly, three individuals who were not included in the study 
because they did not have AMS took 1500 mg of acetazolamide in a 
single dose at 5400m and developed severe headache and nausea. 
Bradwell and colleagues concluded that acetazolamide is 
effective in the treatment of AMS. However, there are several 
problems with this study. First, acetazolamide doses of 1500 mg 
are higher than any reported previously for the prophylaxis of AMS. 
Because higher doses inhibit red cell CA as well as renal CA, lower 
doses may be more efficacious than higher doses. Second, at the 
doses used in this study, a true double blind design probably was 
not maintained. As Sutton points out, the frequency of paresthesia 
and increased urination make it difficult to conduct a true double 
blind study with acetazolamide (80). Lastly, ear lobe capillary 
P02 levels are not accurate with local reductions in blood flow 
(20), as may occur at high altitude because of peripheral 
vasoconstriction secondary to cold, stress, and hypoxemia. 
Hackett has also proposed that acetazolamide might be useful 
in the treatment of AMS. In an uncontrolled study of five subjects 
with AMS, acetazolamide reduced the A-a gradient for 02 (Hackett, 
personal communication). This study suggested that acetazolamide 
may be beneficial in the treatment of AMS in part because it 
improves pulmonary gas exchange. A decreased (A-a)D02 combined 
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with the increase in ventilation seen with acetazolamide might lead 
to marked improvements in blood oxygenation and symptoms. 
VI.B. HYPOTHESIS AND SPECIFIC AIMS 
The purpose of this thesis was to validate the current 
clinical use of acetazolamide in the treatment of AMS, and to 
further investigate the effect of acetazolamide on gas exchange, 
in a placebo controlled clinical trial. The hypothesis was that 
acetazolamide is useful in the treatment of AMS because it relieves 
symptoms and improves pulmonary gas exchange. In order to confirm 
or refute the hypothesis the specific aims of this study were to: 
1) determine the efficacy of acetazolamide in the treatment of AMS 
as judged by symptom scores; 2) determine the effect of 
acetazolamide on the A-a gradient for 02 in individuals with AMS; 
3) observe the correlation between change in symptoms of AMS and 
change in the A-a gradient in AMS. 
If acetazolamide improves the symptoms of AMS and improves 
pulmonary gas exchange, it would support a current clinical use of 
acetazolamide, and would suggest one possible mechanism for 
acetazolamide's benefit in the treatment of AMS. Improvement in 
gas exchange might directly relieve those AMS symptoms due to 
pulmonary dysfunction. Improvement in gas exchange would also 
improve cerebral oxygen delivery, and might relieve those AMS 
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symptoms attributed to CNS hypoxia. If acetazolamide improves gas 
exchange it might also be useful in the prophylaxis of HAPE. The 
low grade pulmonary edema that presumably causes the impaired gas 
exchange in AMS could be the precursor of HAPE, and thus treatment 
of AMS might prophylax against HAPE. 
If acetazolamide improves the symptoms of AMS but does not 
improve gas exchange, it would indicate that there may be other 
beneficial mechanisms of acetazolamide that require further 
investigation. For example, acetazolamide may be useful in AMS 
because of its ability to lower CSF production and volume, perhaps 
decreasing intracranial pressure (75). 
Finally, if this study shows that acetazolamide does not 
improve the symptoms of AMS, but does improve pulmonary gas 
exchange, it would suggest that functional changes in the central 
nervous system may have occurred in AMS that cannot be reversed by 
improving pulmonary function. It also would indicate that current 
clinical use of acetazolamide for therapy of AMS might be 
inappropriate. 
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VI.C. METHODS 
Site of Project: 
This study took place during a four week period in June 1989 
at the Denali Medical Research Project high altitude research 
station on Mt. McKinley (Denali), Alaska, where studies on high 
altitude illness have taken place since 1982. All high altitude 
studies were completed in a heated (15°C) laboratory shelter 
(Weatherport, Gunnison, CO) on a glacier at 4200m, on the West 
Buttress Route of Denali. This medical research facility is 
located at the "14,000 ft. camp" on the West Buttress Route which 
was attempted by over 700 climbers during the May to June climbing 
season in 1989. Because of its location on a large glacial shelf 
at an altitude that is ideal for acclimatization before attempting 
the 6150m summit of Mt. McKinley, the 14,000 ft. camp is 
continuously occupied during May and June. This provides an ideal 
population for the study of altitude illness, especially given the 
excellent cooperation from climbers in participating in medical 
research on Denali. Climbers reach the 14,000 ft. camp after 
ascending from the air landing strip at 2100m (7,000 ft.) on the 
Kahiltna glacier. This takes about one week depending on the size 
and strength of the party. 
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Subjects: 
Subjects with AMS, and with onset of symptoms at 4200m within 
24 hours, were recruited from among approximately 350 climbers that 
passed through the 14,000 ft. camp during June 1989. Approval for 
this study was obtained from the University of Alaska Anchorage 
Institutional Review Board, and informed consent was obtained from 
volunteers. Information regarding the study and the inclusion 
criteria (Table 1) were conveyed to the climbing community through 
discussions with climbers and guides. The medical research camp 
is located about 30 meters from the climbers' camp, and many 
climbers come to the medical research camp to ask questions, to 
obtain medical care, or simply to have their percent saturation of 
hemoglobin with oxygen (Sa02%) measured with a digital pulse 
oximeter. In that case information about the study was discussed 
with the climbers. 
Table 1. Inclusion and Exclusion Criteria 
Inclusion Criteria: Exclusion Criteria: 
1. AMS as judged by 1. Acetazolamide use within the past week. 
symptom scores.* 2 . Sulfa allergy.** 
2 . Less than 60 years 3. HAPE. 
of age. 4 . HACE. 
5. Heart disease. 
6. Renal disease. 
7 . Liver disease. 
8. Pregnancy. 
*refer to Table 2 
** Subjects with a history of sulfa-drug allergy were excluded from 
the acetazolamide group and were non-randomly assigned to the 
placebo group. 

47 
The study group consisted of 12 volunteers, 11 men and one 
woman, from the climbers' camp at 4200m on Denali. With an 
incidence of AMS on Denali of 30% (32), about 100 of the climbers 
passing through the 14,000 ft. camp during the time period of this 
study would have had AMS at some point during their climb. Several 
factors account for the small size of the study group compared to 
a relatively large number of potential subjects. First, only 
subjects who experienced symptoms of AMS at 4400m were included in 
the study. Some climbers experience symptoms of AMS before 
reaching the 4400m, and may delay their climb at lower altitudes 
until symptoms resolve. Other climbers may not experience symptoms 
until reaching 5150m (the 17,000 ft. camp) . Even if those with AMS 
at 5150m descended to 4400m, they were not used in the study 
because symptoms would most likely improve with descent. Secondly, 
the benefit of acetazolamide in the prophylaxis of AMS is well 
known among climbers on Denali. Some take acetazolamide 
prophylactically, or therapeutically, even though the benefit of 
acetazolamide in the treatment of AMS is unproven. Lastly, not all 
individuals with AMS agreed to enter the study. 
Assessment of AMS: 
The AMS Symptom Questionnaire was used to diagnose AMS and 
evaluate severity (Table 2) . The AMS Symptom Questionnaire has 
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been used in several studies requiring diagnosis and evaluation of 
AMS (31,25, 26) . Scores on the AMS Symptom Questionnaire also 
correlate well with scores on the Environmental Symptom 
Questionnaire (25) used by other authors (50,55). 
The AMS Symptom Questionnaire, along with an interview and 
examination technique, was used by an investigator to evaluate 
seven different AMS symptoms. Milder symptoms received a score of 
1, and more severe symptoms received a score of 2 or 3. For some 
symptoms the interviewer graded severity, assigning a score of 1, 
2, or 3. For other symptoms, only mild or only severe, scoring was 
predetermined. For example, insomnia, as defined by difficulty 
falling asleep or frequent awakening, received a score of 1. 
Dizziness received a score of 1. Lassitude, in contrast, received 
a score of 3 if the severity was such that a subject required 
assistance with tasks of daily living. Less severe lassitude was 
not scored in the AMS Symptom Questionnaire, as it was subjectively 
difficult to evaluate. An AMS symptom score of 2 or greater was 
used to diagnose AMS. 
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SYMPTOM 
Table 2. AMS Symptom Questionnaire 
REMARKS SCORE 
Headache transient, relieved with analgesic 
severe or not relieved with analgesic 
1 
2 
Insomnia difficulty falling asleep, frequent waking 1 
Dizziness 1 
Ataxia difficulty maintaining balance 1 
steps off line 2 
falls to ground or cannot finish test 3 
Severe requires assistance for tasks of daily 3 
Lassitude living 
Anorexia or true anorexia, not distaste for diet 1 
Nausea 
Vomiting 2 
Dyspnea on dyspnea forces frequent halts, slow 2 
Exertion to recover 
Dyspnea at marked dyspnea at rest 3 
Rest 
A global functional assessment was also made at the t ime 
the interview and examination by the evaluating investigator (Table 
3) . On a scale of 0 to 4 this estimated the overall degree of 
impairment of the subject's activities with respect to continuing 
or halting ascent. 
Global 
Functional 
Assessment 
Table 3. Global Functional Assessment 
no symptoms 
symptoms, but able to continue 
symptoms, stopping ascent 
intensive medical treatment and/or 
evacuation to lower altitude required 
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Double Blind Study Design: 
Entrance criteria required that subjects had symptom scores 
of 2 or greater on the AMS Symptom Questionnaire. Baseline 
evaluation included a physical examination and measurements of 
pulse, blood pressure, and respiratory rate. The percent 
saturation of hemoglobin with oxygen (Sa02%) was measured with the 
subject in the sitting position using a portable finger pulse 
oximeter (Criticare 503+). Spirometry measurements included forced 
vital capacity (FVC) and peak expiratory flow (PEF) . FVC was 
measured with a hand held turbine spirometer (Boehringer 
Laboratories, Wynnewood, PA) and PEF was measured with a mini- 
Wright's peak flow meter (Clement Clark, Ltd., England). End tidal 
C02 (PetC02) was measured with the subject in the sitting position 
using an infra-red C02 analyzer (Beckman LB-2). A baseline 
arterial blood gas sample was drawn into a heparinized syringe from 
the radial artery after infiltration with lidocaine. 
After the above baseline measurements, subjects were randomly 
assigned to receive either acetazolamide or placebo in a double 
blind fashion. Subjects reporting a history of sulfa-drug allergy 
were non-randomly assigned to the placebo group (one subject). The 
dose of acetazolamide was 250 mg or placebo at time zero, and 
acetazolamide 250 mg or placebo at eight hours. Packets assigning 
randomization to acetazolamide or placebo were prepared in blocks 
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of four by an independent observer from the staff of the medical 
research camp. The same independent observer administered doses 
of acetazolamide or placebo by crushing 250 mg acetazolamide 
tablets and mixing with an orange drink or by giving an equal 
amount of orange drink alone. The principal investigator was not 
present during preparation or administration of the study drug. 
After the above baseline measurements subjects returned to their 
camp. Subjects were not permitted to use any self prescribed drugs 
during the study. 
Subjects presented to the medical research camp eight hours 
after entry to receive the second dose of acetazolamide or placebo. 
Measurements of pulse, respiratory rate, and Sa02% were repeated. 
Subjects again returned to their camp. 
Subjects presented to the medical research camp at 24 hours 
after inclusion for a repeat assessment of AMS symptoms using the 
AMS Symptom Questionnaire. A physical examination was done that 
included measurement of pulse, respiratory rate, blood pressure, 
and Sa02%. Measurements of FVC, PEF, and PETC02 were repeated. A 
second arterial blood gas sample was drawn from the radial artery. 
This concluded the double blind portion of the study. 
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Single Blind Crossovers: 
At the end of 24 hours, after the second assessment of AMS 
symptoms, physical exam, and physiological measurements, subjects 
who still had a symptom score of 2 or greater were offered the 
option of crossing over in the study by the independent observer. 
Three subjects agreed, and all crossed over from placebo to 
acetazolamide. The only subject from the acetazolamide group 
eligible to crossover to placebo, subject 6, declined to continue 
in the study. Following their decision to continue in the study, 
the independent observer revealed to all three subjects who crossed 
over from placebo to acetazolamide that they had been on placebo 
during the first 24 hours. This was done at the subjects' request. 
Investigators involved in the study remained blinded as to whether 
the subject was on acetazolamide or placebo. 
Subjects choosing to crossover were given acetazolamide 250 
mg at 24 hours and again at 32 hours after initial entry. At 48 
hours another assessment of AMS using the AMS Symptom Questionnaire 
was done, and a physical examination was performed that included 
measurement of pulse, blood pressure, respiratory rate, and Sa02%. 
PEF, FVC, and PETC02 were measured using the same methods as at time 
zero and 24 hours and a third arterial blood gas sample was drawn 
from the radial artery. 
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Measurement of (A-a)D02: 
Arterial blood gas samples drawn at time zero and at 24 and 
48 hours were used for measurement of the arterial partial pressure 
of oxygen (Pa02) and partial pressure of carbon dioxide (PaC02) 
using a blood gas analyzer (Instrumentation Laboratories Micro 13). 
All samples were placed on ice and analyzed within 30 minutes. 
The partial pressure of alveolar oxygen (PA02) was calculated 
from a simplified version of the alveolar air equation, (PA02 = 
PI02 - PAC02/R), assuming a respiratory exchange ratio (R) of 0.85 
(1890) . The partial pressure of alveolar carbon dioxide (PAC02) 
was determined from end tidal C02 using an infra-red C02 analyzer 
(Beckman LB-2). The apparent respiratory exchange ratio was 
measured for two subjects using standard techniques (88) . The 
respiratory exchange ratio was .80 for subject 9 and .88 for 
subject 10. 
Data Analysis: 
Change in (A-a)D02 over 24 hours in the acetazolamide and 
placebo groups were compared using the Mann-Whitney Rank-Sum test 
(two-tailed). Symptom score data from the placebo and 
acetazolamide groups were compared using the Mann-Whitney U-test 
(two-tailed). Correlation between change in AMS symptom score over 
24 hours and change in (A-a)D02 over 24 hours in both the 

54 
acetazolamide and placebo groups was evaluated using the Spearman 
Rank Correlation Coefficient. Change in Sa02%, PEF, FVC, PETC02, 
PaC02, and Pa02 over 24 hours in the acetazolamide and placebo 
groups were compared using the Mann-Whitney Rank-Sum test. For 
all methods used in data analysis, a p value of less than .05 was 
accepted as indicating statistical significance. 
Nonparametric methods were used to determine statistical 
significance rather than the more commonly used parametric methods, 
such as Student's t test. Parametric methods are based on the 
assumption that the observations are drawn from normally 
distributed populations. When the sample size is small or when the 
population studied deviates from normality, interpreting the mean 
and standard deviation in terms of a normal distribution may give 
a misleading picture. In contrast, nonparametric methods use 
information about the relative sizes of the observations and does 
not assume that the sample population is representative of a 
normally distributed population. When the observations are drawn 
from populations that are not normally distributed, nonparametric 
methods are not only more reliable but also more powerful (19) . 
Nonparametric methods are therefore more appropriate in this study 
for two reasons. First, the sample size is small. Second, the 
observations are made at high altitude where the normal 
distribution of physiologic parameters is not well documented. 
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VI.D. RESULTS 
Subject Population: 
The 12 subjects included 11 men and one woman ranging in age 
from 25 to 46. All subjects lived at sea level and were non- 
smokers, except for subject 1 who smoked cigarettes. The average 
number of days spent climbing from 2100m to 4400m was 8.9, and the 
average number of nights at the 14,000 ft. camp before inclusion 
in the study was 1.8. Nine out of the 12 subjects reported a past 
history of altitude illness. Of those nine, three had a past 
history of AMS and high altitude headache, four had a past history 
of AMS without high altitude headache, and two gave a past history 
of high altitude headache alone. None of the subjects reported a 
past history of HAPE or HACE. All subjects had climbed above 3000m 
prior to their attempt on Denali, eight had climbed above 4000m, 
and two had climbed to 6800m in South America. Seven subjects were 
members of guided parties. The subject populations randomized to 
receive placebo or acetazolamide are compared in Tables 4 and 5. 
All subjects in the study had Global Functional Assessment 
Scores of 1 or 2, and these data are not listed in the results. 
Instead, success in reaching the summit after concluding the study 
was used as a general indicator of the overall degree of impairment 
of the subject's activities with respect to continuing or halting 
ascent. This information is listed in Tables 4 and 5 under 
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comments as reached summit, attempted summit, or descended. 
Table 4. High Altitude History: Placebo Group 
Sub Sex Age 
Altitude* * * 
Climbing Hx 
Hx of High** 
Altitude Illness 
nights at 14K* 
Prior to Study 
#3 M 37 4000 m AMS and Headache 1 
#4 M 46 3000 m none 2 
#5 F 31 6800 m AMS 3 
#8 M 42 3000 m none 2 
#10 M 32 4000 m AMS 1 
#12 M 40 4000 m AMS 1 
mean age= 38.0 +5.8 SD mean # nights= 1.7 
Table 5. High Altitude History: Acetazolamide Group 
Sub Sex Age 
Altitude* * * 
Climbinq Hx 
Hx of High** 
Altitude Illness 
nights at 14K* 
Prior to Study 
#1 M 32 6800 m AMS and Headache 1 
#2 M 28 4000 m Headache 3 
#6 M 25 3000 m AMS and Headache 3 
#7 M 29 4 0 0 0 m AMS 0 
#9 M 32 3000 m Headache 1 
#11 M 31 3000 m none 3 
mean age= 29.5 +2.7 SD mean # nights= 2.0 
*** Altitude climbing history denotes approximate highest altitude 
reached on previous climbs. Choices were above 3000 m, above 
4000 m, or if above 5000 m then actual altitude. 
** Choices for history of altitude illness were AMS, high 
altitude headache, HACE, or HAPE. 
* Number of nights at 14,000 ft. camp before inclusion in study. 
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Table 6. AMS Symptom Scores: Placebo Group 
AMS Symptom Score** Change in*** 
Subj 0 hrs 24 hrs AMS Score Comments 
#3 5 4 (-1) descended-" 
#4 6 2 (-4) reached summit 
#5 5 2 (-3) attempted summit 
#8 2 3 ( + 1) reached summit" 
#10 2 2 ( 0) reached summit" 
#12 3 2 (-1) reached summit 
mean* 3.8 +.7 2.5 +.3 (-1.3 +.8) 
Table 7. AMS Symptom Scores: Acetazolamide Group 
AMS Symptom Score** Change in*** 
Subi 0 hrs 24 hrs AMS Score Comments 
#1 4 1 (-3) reached summit 
#2 4 1 (-3) not known 
#6 4 2 (-2) descended 
#7 3 1 (-2) developed HAPE 
#9 4 1 (-3) reached summit 
#11 4 0 (-4) descended 
mean* 3.8 +.2 1.0 +.2 (-2.8 +.3) 
* For both groups n=6, mean +. SE is given. 
** p<.01 for comparison of symptom score after 24 hours between 
groups, Mann-Whitney U-test. 
*** p>.05 for comparison of change in symptom score over 24 hours 
between groups, Mann-Whitney U-test. 
+ Crossover to acetazolamide after double blind study. 

Figure 1. Change in AMS Symptom Score: Acetazolamide Group 
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Figures 1 and 2. Change in AMS symptom score over 24 hours 
in the acetazolamide and placebo groups. The dark horizontal 
dashed line corresponds to a symptom score of 2, the minimum 
symptom score defining AMS. Assessment of AMS was made at 0 
and 24 hours. Change in symptom score over 24 hours for each 
subject is indicated by the solid lines. Mean change in 
symptom score for each group is indicated by the light dashed 
lines. Error bars indicate ± standard error for the mean at 
0 and 24 hours. 
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Table 8. Presence or Absence of AMS after 24 Hours 
AMS* Healthy* 
Acetazolamide 1 5 
Placebo 6 0 
p<.05* * 
* "AMS" indicates the number of subjects who had clinically 
defined AMS after 24 hours as defined by symptom scores of 2 or 
greater. "Healthy" indicates the number of subjects who had symptom 
scores of less than 2 after 24 hours. 
** Mann-Whitney U-test. 
AMS Symptom Score Data: 
Inclusion criteria dictated that all subjects entering the 
study had AMS symptom scores of 2 or greater. Twelve subjects were 
entered into the double blind portion of the study with equal 
numbers in the acetazolamide and placebo groups. Subject 12 was 
non-randomly assigned to the placebo group after reporting a 
history of sulfa-drug allergy. 
Symptom score data are shown in Tables 6 and 7. At 24 hours 
five out of six subjects in the acetazolamide group were healthy 
with AMS symptom scores of less than 2, and all six subjects in the 
placebo group still had AMS with symptom scores of 2 or greater 
(p< .05, Table 8) . The one subject in the acetazolamide group still 
exhibiting clinically defined AMS after 24 hours (subject 6) had 
an AMS symptom score of 2, improved from an initial score of 4. 
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AMS symptom score after 24 hours was also significantly 
different between groups (pc.Ol, Tables 6 & 7) . However, the 
change in AMS symptom score over 24 hours was not significantly 
different between groups (p>.05, Tables 6 & 7). The improvement 
in symptom score over 24 hours occurring in both groups is 
graphically displayed in Figures 1 and 2. 
Change in (A-a)DQ2 and Pa02: 
Data on (A-a)D02 was not obtained on all subjects during the 
double blind portion of the study because some radial puncture 
samples had values more consistent with venous blood and the 
subjects declined a second attempt at a radial artery blood draw. 
Data on change in (A-a)D02 over 24 hours were obtained in three 
subjects in the acetazolamide group and six subjects in the placebo 
group. In the acetazolamide group two out of three subjects had 
a decrease in (A-a)D02 over 24 hours, and in the placebo group five 
out of six subjects had an increase in (A-a)D02 over 24 hours. 
Change in (A-a)D02 over 24 hours was significantly different 
between the placebo and acetazolamide groups at the p<.05 level 
(Table 9,Figures 3 & 4). This appears to be more a result of an 
increase in the A-a gradient in the placebo group, rather than a 
decrease in the A-a gradient in the acetazolamide group. 
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Data on change in Pa02 over 24 hours was obtained on three 
subjects in the acetazolamide group and six subjects in the placebo 
group. All three subjects in the acetazolamide group increased 
their Pa02 over 24 hours, and four out of 6 in the placebo group 
decreased their Pa02 over 24 hours. Change in Pa02 over 24 hours 
was significantly different between the placebo and acetazolamide 
groups at the p<.05 level (Table 10,Figures 5 & 6). 
Changes in PaC02, PETC02, Sa02%, FVC, and PEF over 24 hours 
were not significantly different between the acetazolamide and 
placebo groups (Table 11). A larger sample size, however, might 
have revealed significant differences in the change of some of 
these parameters between the acetazolamide and placebo groups. 
For example, the mean change in PaC02 for the acetazolamide group 
appears significantly different from the mean change in PaC02 for 
the placebo group. However, nonparametric methods, which do not 
rely on mean values, were used to determine statistical 
significance. 
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Table 9. Chanqe in (A- a)D02 Over 24 hrs in Double Blind Study 
Subiect 
Acetazolamide 
(A-a)D02 in torrs Subiect 
Placebo 
(A-a)D02 in Torrs 
- 
Ohrs 24hrs Change Ohrs 24hrs Change 
#6 8.2 8.5 (+0.3) #3 7.3 10.4 (+3.1) 
#9 12.1 11.4 (-0.7) #4 12.2 12.1 (-0.1) 
#11 6.8 4.7 (-2.1) #5 5.2 7.0 (+1.8) 
#8 14.3 18 . 9 (+4.6) 
#10 10.8 14 . 8 (+4.0) 
#12 2.9 9.4 (+6.5) 
mean = (-0.8) mean = (+3.3) 
SE = + 0.7 p<.05* SE = + 0.9 
* Change in (A-a)D02 is significantly different between the placebo 
and acetazolamide groups using the Mann-Whitney Rank-Sum Test. 
Table 10. Change in Pa02 Over 24 Hours in Double Blind Study 
Acetazolamide Placebo 
Subiect Pa02 in torrs Subiect Pa02 in torrs 
Ohrs 24hrs Change Ohrs 24hrs Change 
#6 40.5 44.0 (+3.5) #3 47.0 42.0 (-5.0) 
#9 41.0 44.3 (+3.3) #4 43.0 44.0 (+1.0) 
#11 51.0 53.0 (+2.0) #5 50.0 53.0 (+3.0) 
#8 42.0 40.0 (-2.0) 
#10 43.0 40.0 (-3.0) 
#12 46.0 44.0 (-2.0) 
mean = (+2.9) mean = (-1.4) 
SE = + 0.5 p<.05* SE = ±1.2 
* Change in Pa02 is significantly different between the placebo 
and acetazolamide groups using the Mann-Whitney Rank-Sum Test. 
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Table 11. Change in C02, Sa02 and Spirometry: Double Blind Study 
(all values are mean _+ SE) 
Acetazolamide * Placebo 
Ohrs 24hrs Change Ohrs 24hrs Change 
Pa02 (torrs) 44.2 47.1 (+2.9) 45.2 43.8 (-1.4) 
n=* * + 3.4 + 2.9 + 0.5 + 1.3 + 2.0 + 1.2 
PaC02 (torrs) 28.2 25.6 (-2.5) 28.3 28.4 (+0.1) 
n=* * + 1. 6 + 0.9 + 1.8 + 0.9 + 0.6 + 0.6 
PetC02+ (torrs) 26.1 24.3 (-1.8) 25.0 23.3 (-1.7) 
n=6 + 1.5 + 0.7 + 0 . 9 + 1.0 + 1. 1 + 0 . 9 
Sa02 % 78.2% 82.5% (+4.3%) 81.2% 85.2% (+4.0%) 
n=6 + 2.9 + 2.2 + 0.9 + 1.7 + 0.9 + 1.3 
PEF (lit/sec) . 603 .584 (-.019) .563 . 572 (+.009) 
n=6 + . 044 + . 049 + .014 + . 034 + .098 + .015 
FVC (liters) 3.21 3.20 (-0.01) 3.18 3.12 (-0.06) 
n=6 + . 11 + .21 + 0.13 ±. 31 + . 30 + 0.11 
* For all data except Pa02, p>.05 for comparison of change over 24 
hours between groups (Mann-Whitney Rank-Sum test) . 
** Mean Pa02 and PaC02 values are for n=3 in the acetazolamide 
group and n=6 in the placebo group. All other mean values are for 
n=6. 
+ PetC02 was used for calculation of (A-a)D02 in all subjects. 

64 
Figure 3. Change in (A-a)D02: Acetazolamide Group 
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Figures 3 and 4. Change in A-a gradient for 02 over 24 hours 
in the acetazolamide and placebo groups. For the 
acetazolamide group n=3, and for the placebo group n=6. 
Change in (A-a)D02 over 24 hours is shown for each subject 
by the solid lines, and mean change in (A-a)D02 over 24 hours 
is shown for each group by the dashed lines. Error bars 
indicate ± standard error for the mean at 0 hours and at 24 
hours. 
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Figure 5. Change in Pa02: Acetazolamide Group 
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Figures 5 and 6. Change in Pa02 over 24 hours in the 
acetazolamide and placebo groups. For the acetazolamide 
group n=3, and for the placebo group n=6. Change in Pa02 
over 24 hours is shown for each subject by the solid lines, 
and mean change in Pa02 over 24 hours is shown for each group 
by the dashed lines. Error bars indicate + standard error 
for the mean at 0 and 24 hours. 

Correlation of Change in (A-a)D02 and Change in Symptom Score: 
For the acetazolamide and placebo groups combined, 
correlation between change in the symptom score and change in 
(A-a)D02 over 24 hours was significant (p<.005, Figure 7). 
Acetazolamide was associated with a decrease in (A-a)D02 and a 
greater improvement in symptom score, while placebo was 
associated with an increase in (A-a)D02 and less of an 
improvement in symptomn score. 
Figure 7. Change in (A-a)D02 versus Change in AMS Symptom Score 
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Figure 7. Change in AMS symptom score over 24 hours is plotted 
against change in A-a gradient for 02 over 24 hours using data 
from both the acetazolamide (n=3) and placebo (n=6) groups. 
Correlation between change in (A-a)D02 and change in symptom 
score over 24 hours is significant at the p<.005 level (Spearman 
Rank Correlation Coefficient, rs=.87). 
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Single Blind Crossover Data: 
Data on single blind crossovers from placebo to acetazolamide 
are shown in Table 12 and Figures 8 & 9. In all three subjects (A- 
a) D02 increased and Pa02 decreased with placebo, and in two of 
three subjects symptom score did not improve with placebo. This 
contrasts with acetazolamide-treatment which was associated with 
a narrowing of (A-a)D02, an increase in Pa02, and an improvement 
in symptom score. 
Table 12. Data for Crossovers from Placebo to Acetazolamide* ** 
PLACEBO ACETAZOLAMIDE 
AMS Symptom Score AMS Symptom Score 
Subi* * Ohrs 2 4hrs Change 24hrs 4 8hrs Change 
#3x 5 4 (-1) 4 0 (-4) 
#8x 2 3 ( + 1) 3 1 (-2) 
# 1 Ox 2 2 ( 0) 2 0 (-2) 
(A-a) D02 in torrs (A-a)D02 in Torrs 
Sub j Ohrs 24hrs Change 24hrs 4 8hrs Change 
#3x 7.3 10.4 (+3.1) 10.4 8.3 (-2.1) 
#8x 14.3 18.9 (+4.6) 18.9 8.3 (-10.6) 
# 1 Ox 10.8 14.8 (+4.0) 14 . 8 7.8 (-7.0) 
Pa02 in torrs Pa02 in torrs 
Sub j Ohrs 24hrs Change 24hrs 4 8hrs Change 
#3x 47.0 42.0 (-5.0) 42.0 49.0 (+7.0) 
#8x 42.0 40.0 (-2.0) 40.0 50.0 (+10.0) 
#10x 43.0 40.0 (-3.0) 40.0 49.0 (+9.0) 
* All subjects received placebo (0-24hrs) as part of the double 
blind study, then crossed over to acetazolamide (24-48hrs) in 
a single blind fashion (blinded to investigator). 
** After conclusion of the study subject 3x descended from 4200m. 
Subjects 8x and lOx eventually reached the summit. 

Figure 8. Change in (A-a)D02: Crossovers from Placebo to Acetazolamide 
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Figure 8. Change in (A-a)D02 over 48 hours for crossovers 
from placebo to acetazolamide (n=3). (A-a)D02 at 0 hours is 
baseline, (A-a)D02 at 24 hours is after placebo, and (A-a)D02 
at 48 hours is after acetazolamide. 
Figure 9. Change in Pa02: Crossovers from Placebo to Acetazolamide 
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Figure 9. Change in Pa02 over 48 hours for crossovers from 
placebo to acetazolamide (n=3). Pa02 at 0 hours is baseline, 
Pa02 at 24 hours is after placebo, and Pa02 at 48 hours is 
after acetazolamide. 
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VI.E. DISCUSSION 
In this study comparing acetazolamide to placebo in the 
treatment of 12 climbers with AMS at 4200m on Denali several 
observations were made: 1) Acetazolamide 250 mg administered in 
two doses eight hours apart was more effective than placebo in 
treating AMS; 2) Acetazolamide improved pulmonary gas exchange 
and Pa02 over 24 hours in AMS as compared to placebo; 3) A 
decrease in the A-a gradient over 24 hours correlated with a 
greater improvement in symptom score in the acetazolamide group, 
and an increase in the A-a gradient over 24 hours correlated with 
less of an improvement in symptom score in the placebo group. 
Therefore, acetazolamide is effective for the treatment of 
established cases of AMS, and is associated with an improvement in 
pulmonary gas exchange. Furthermore, the significant correlation 
between change in the A-a gradient and change in symptoms of AMS 
over 24 hours suggests that impaired pulmonary gas exchange 
contributes to the symptoms of AMS. 
All subjects tolerated the study without complications, 
although subject 7 developed HAPE 24 hours after conclusion of the 
study and 40 hours after acetazolamide treatment. This indicates 
that acetazolamide at the dose used in this study is not completely 
effective in prophylaxis for HAPE. 
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Six of the 12 subjects in the study eventually reached the 
summit of Denali. Two of those who reached the summit received 
only placebo in the study and still had clinically defined AMS 
after 24 hours. Three subjects never made a summit attempt and 
descended from 4200m, and two of those did not have clinically 
defined AMS after completing the acetazolamide portion of the 
study. Therefore, AMS does not preclude summit success and 
acetazolamide treatment of AMS does not guarantee summit success. 
Symptom Score Data: 
Both the acetazolamide and placebo groups in this study showed 
improvement in symptom score over 24 hours. This was expected 
because AMS improves with time in most individuals if ascent is 
halted. The significant finding in this study, though, was that 
after 24 hours five out of six subjects in the acetazolamide group 
did not have AMS, whereas all six subjects in the placebo group 
still had clinically defined AMS. This indicates that 
acetazolamide speeds the process of acclimatization and shortens 
the period of symptomatic illness in AMS. 
Although AMS symptom score after 24 hours was significantly 
different between groups (pc.Ol, Tables 7 & 8), the change in AMS 
symptom score over 24 hours was not significantly different between 
groups (p>.05, Tables 7 & 8). However, comparison of the mean 
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change in symptom score over 24 hours for the acetazolamide group 
(-2.8 +.0.3) with the mean change for the placebo group (-1.3 ±0.8), 
suggests that a larger sample size might have shown a significant 
difference in change of symptom score over 24 hours between groups. 
The efficacy of acetazolamide as compared to placebo in 
treating established cases of AMS in this study may be criticized 
because of an improvement with time bias in the acetazolamide group 
itself. Two aspects of the study minimize this bias. First, the 
number of nights spent at 4200m before inclusion in the study was 
similar for both the acetazolamide and placebo groups. Therefore, 
both the acetazolamide and placebo groups were equally likely to 
experience improvement in symptoms because of the natural history 
of AMS. Second, a more powerful controlling factor for improvement 
with time bias was present in the study design. Subjects started 
this study within 24 hours of onset of symptoms at 4200m, thus 
minimizing the chance of enrolling a subject in the study who was 
nearing the end of their course of AMS. This is ultimately more 
reliable in ensuring that subjects are not already improving when 
they enter the study. Symptoms of AMS may occur from several hours 
to several days after ascent to a higher altitude. Therefore, some 
individuals may experience symptoms upon arrival at 4200m, while 
other individuals may not experience symptoms until after sleeping 
one or two nights at 4200m. This makes time of onset of symptoms, 
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rather than the number of nights at 4200m, a more accurate 
parameter to follow the natural course of AMS. 
The symptom score data in this study might also be criticized 
because of non-random assignment of subject 12 to the placebo 
group. In the study design a small number of subjects was 
anticipated, and allowance was made for subjects with a sulfa-drug 
allergy to participate as controls. Non-random assignment of 
subject 12 to the placebo group might have introduced bias in the 
symptom score data. Symptom scores rely on subjective criteria 
that might be reported differently by an individual more sensitive 
to the effects of drug therapy. However, data from physical 
measurements were probably not influenced by subject 12. 
(A-a)D02 and Pa02 Data: 
The change in A-a gradient for 02 over 24 hours was 
significantly different between the acetazolamide and placebo 
groups in this study. The data suggest that this was due more to 
an increase in A-a gradient with placebo than to a decrease in A- 
a gradient with acetazolamide; the mean change in (A-a)D02 in the 
placebo group over 24 hours was +3.3 ±0.9 torr, whereas the mean 
change for the acetazolamide group was -0.8 +0.7 torr. Therefore, 
acetazolamide improved pulmonary gas exchange over 24 hours when 
compared to placebo in this study because it prevented the increase 
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in A-a gradient observed in the placebo group. Although two out 
of three subjects in the acetazolamide group decreased their A-a 
gradient over 24 hours, a larger sample size would have been 
required to further conclude that acetazolamide significantly 
decreased the A-a gradient. Further studies with larger sample 
sizes will need to confirm this. 
Hackett has reported that some individuals with AMS have an 
increased A-a gradient with values of 15-16 torr, as opposed to 
healthy individuals with A-a gradients at altitude of approximately 
7 torr (38) . Some subjects in this study had elevated A-a 
gradients according to Hackett's parameters: subjects 8 and 10 with 
A-a gradients of 18.9 and 14.8 torr after 24 hours in the placebo 
group. However, the data in this study suggest a range of values 
for A-a gradient in individuals with AMS, rather than a group of 
"normal" values, and second group of "abnormal" values. 
Furthermore, AMS in the placebo group in this study was 
characterized by worsening gas exchange over 24 hours. It might 
be that impairment in pulmonary gas exchange in AMS is a continuum 
from normal to severe, and that worsening pulmonary gas exchange 
occurs over time in AMS. 
The significant difference in change of (A-a)D02 over 24 hours 
between acetazolamide and placebo may be questioned because the age 
difference between the placebo group and the acetazolamide group 
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may have influenced the data. The mean age of the placebo group 
(38.0 + 5.8 SD) was older than the mean age of the acetazolamide 
group (29.5 +_ 2.7 SD). Since ventilation perfusion mismatch and 
(A-a)D02 increase with age, this may have biased comparisons 
between the acetazolamide and placebo groups. However, this study 
compares change in (A-a)D02 rather than the absolute values of (A- 
a)D02 for each subject. Still, stratifying the study for age would 
have been helpful. 
The increase in Pa02 observed in the acetazolamide group and 
the decrease in Pa02 observed in the placebo group may have 
occurred for two reasons. First, a decrease in (A-a)D02 with 
acetazolamide treatment may account for the increase in Pa02 in the 
acetazolamide group but, as discussed above, this cannot be 
confirmed by this study. An increase in (A-a) gradient was 
observed in the placebo group, however, and may have contributed 
to the decrease in Pa02 over 24 hours in the placebo group. 
Second, Pa02 will increase if minute ventilation is increased, even 
if (A-a)D02 is unchanged. The increase in minute ventilation with 
acetazolamide therapy is well documented (57), and may have 
accounted for the increase in Pa02 in the acetazolamide-treated 
subjects in this study. Likewise, the decrease in Pa02 observed 
in the placebo group may have occurred because of relative 
hypoventilation known to occur in AMS (29,78). Direct measurements 
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of minute ventilation in this study would have been helpful in 
confirming a change in minute ventilation as a cause of the 
significant difference in change of Pa02 over 24 hours in the 
acetazolamide as compared to the placebo groups. Data on change 
in PaC02 were not helpful in suggesting an increase in minute 
ventilation in the acetazolamide group, as the change in PaC02 over 
24 hours was not significantly different between groups. 
Acetazolamide and Pulmonary Gas Exchange: 
The increased baseline (A-a)D02 observed in some individuals 
with AMS (38,78) is probably indicative of increased extravascular 
lung water with early interstitial edema. Increasing lung leak 
might also have contributed to the worsening pulmonary gas exchange 
in the placebo group observed in this study. Therefore, the 
improved pulmonary gas exchange over 24 hours in the acetazolamide 
as compared to the placebo group in this study might indicate 
decreased extravascular lung water in the acetazolamide-treated 
subjects. The diuretic effect of acetazolamide could explain this. 
Other studies using lasix in the treatment or prophylaxis of AMS, 
however, have shown conflicting results. Singh reported that lasix 
was effective in the treatment of AMS (76) , but Gray observed 
severe AMS in subjects treated prophylactically upon air transport 
to 5400 m (21). In the latter study the authors speculated that 
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dehydration may have contributed to the increased severity of AMS 
in the subjects, and this has discouraged subsequent use of 
diuretics in North America. A study comparing acetazolamide with 
a mild diuretic in the treatment of AMS and their effect on (A- 
a)D02 might help clarify two issues. First, whether diuresis is 
beneficial in the treatment of AMS. Second, whether a diuretic 
effect of acetazolamide is responsible for improvements in gas 
exchange as compared to placebo. 
The increase in Pa02 in acetazolamide-treated subjects in this 
study also suggests a possible mechanism for improved pulmonary gas 
exchange. It might be that the increase in Pa02, due to increased 
minute ventilation known to occur with acetazolamide, indirectly 
improved those factors responsible for increased extravascular lung 
water. An increase in Pa02 might decrease hypoxic pulmonary 
vasoconstriction and pulmonary artery pressure, thereby reducing 
transudation of fluid from the pulmonary vascular bed to the 
interstitial space. This would result in improved pulmonary gas 
exchange and a further increase in Pa02. 
Acetazolamide also might directly influence the pulmonary 
epithelium, vascular endothelium, or vascular smooth muscle, and 
influence factors that contribute to transudation of fluid to the 
interstitium. The presence of carbonic anhydrase in the pulmonary 
capillary endothelium is well established, and it also may be 
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present in alveolar epithelial cells (83) . The full effects of 
inhibition of the different carbonic anhydrase isoenzymes at these 
various sites is not known. 
Some authors suggest that there may be a neurogenic component 
to HAPE, and CNS dysfunction also may contribute to the increased 
extravascular lung water in AMS. Effects of acetazolamide on the 
brain, such as decreased production of CSF (75), may also influence 
the low grade pulmonary edema in AMS. 
End Tidal C02 and PaC02 Data: 
Surprisingly, no difference in change of PETC02 or PaC02 was 
observed between the acetazolamide and placebo groups. In the 
prophylaxis of AMS, acetazolamide increases minute ventilation and 
decreases PaC02 (8,51,57), so it was expected that the PaC02 of the 
treated group would be lower than that of the placebo group in this 
study. However, with the small sample sizes in this study Type II 
error must be considered. A larger sample size might show 
decreases in PETC02 and PaC02 with acetazolamide treatment as 
compared to placebo. As was mentioned above, it would have been 
helpful to measure minute ventilation directly. It also would have 
been helpful to observe whether acetazolamide decreased the 
arterial pH during this study, but the pH electrode on the blood 
gas machine was disabled. 
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It is important that PaC02 did not increase in the 
acetazolamide group during this study. Swenson warns against 
acetazolamide treatment of AMS or HAPE because pulmonary 
dysfunction and relative hypoventilation in AMS may not allow 
ventilatory compensation for the respiratory acidosis secondary to 
RBC carbonic anhydrase inhibition (81) . The doses of acetazolamide 
used in this study were slightly higher than the 5 mg/kg suggested 
to minimize RBC carbonic anhydrase inhibition, yet an increase in 
PaC02 was not observed. However, RBC carbonic anhydrase inhibition 
may explain why no significant decrease in PETC02 or PaC02 were 
observed in the acetazolamide group as compared to the placebo 
group. RBC carbonic anhydrase inhibition in the acetazolamide 
group might have caused a respiratory acidosis (increase in PaC02) 
that was then compensated for with increased ventilation so that 
over 24 hours no significant change in PaC02 was observed. 
Spirometry: 
No significant change in PEF or FVC were observed between the 
acetazolamide and placebo treated groups in this study. Larson and 
colleagues observed an increase in FVC in climbers taking 
acetazolamide prophylactically for AMS during an ascent of Mt. 
Ranier, but the sample size in that study (n=30 in the 
acetazolamide group) was significantly larger than in this study 
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(57) . A larger sample size in this study might have shown 
significant differences in change in spirometric data between the 
acetazolamide and placebo groups. 
Change in (A-a)D02 Versus Change in AMS Symptom Score: 
In the acetazolamide and placebo groups combined, a 
significant correlation between change in A-a gradient for 02 and 
change in symptom score over 24 hours was observed in this study. 
Acetazolamide was associated with a decrease in A-a gradient and 
a greater improvement in AMS symptom score, and placebo was 
associated with an increase in A-a gradient and less of an 
improvement in symptom score. This suggests that impaired 
pulmonary gas exchange contributes to the symptoms of AMS. Although 
symptoms of AMS are more consistent with cerebral dysfunction, 
rather than pulmonary dysfunction, impaired pulmonary gas exchange 
may worsen cerebral hypoxia and thereby exacerbate AMS symptoms. 
Likewise, improving pulmonary gas exchange in AMS may improve 
cerebral hypoxia and improve AMS symptoms. In the acetazolamide- 
treated subjects in this study, improvement in gas exchange was 
associated with a greater improvement in symptoms of AMS. This 
suggests that acetazolamide improves the symptoms of AMS in part 
because it improves pulmonary gas exchange as compared to placebo. 
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Crossover Data: 
Single blind crossovers (blinded to investigator) from placebo 
to acetazolamide in this study showed marked improvements with 
acetazolamide. All crossover subjects increased (A-a)D02 and 
decreased Pa02 with placebo, and two out of three did not improve 
symptom score with placebo. In contrast, all crossover subjects 
decreased (A-a)D02, increased Pa02, and improved symptom score with 
acetazolamide. These findings support the conclusions drawn from 
the double blind study data. However, the crossover data alone are 
not significant because the crossover subjects may have improved 
with -time, and not because of acetazolamide treatment. It would 
have been helpful to study some placebo subjects over 48 hours for 
comparison with the crossover subjects. Other subjects completing 
the placebo portion of the study, though, were unwilling to 
continue as placebo to placebo crossovers. They either experienced 
relief of symptoms and continued climbing or they preferred to take 
acetazolamide rather than risk the chance of taking placebo for 
another 24 hours. 
Acetazolamide Prophylaxis for HAPE: 
Impaired gas exchange in AMS, presumably caused by increased 
extravascular lung water, may be a precursor to HAPE. The 
improvement in pulmonary gas exchange observed in the acetazolamide 
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treated subjects in this study, then, suggests that acetazolamide 
may be useful in the prophylaxis of HAPE. However, subject 7 
offers a case study in the failure of acetazolamide as prophylaxis 
for HAPE. 
On presentation subject 7's chief complaint was a pounding 
bitemporal headache somewhat relieved with analgesics. Additional 
complaints of insomnia and anorexia resulted in an AMS symptom 
score of 3. The subject had no pulmonary symptoms, but on physical 
exam he had a few right middle lobe rales and an Sa02 of 67%. 
Baseline (A-a)D02 data were not obtained because of a venous blood 
sample. At 24 hours the subject reported sleeping better and 
eating better, but still complained of headache, and received a 
symptom score of 1. At 24 hours the right middle lobe rales were 
unchanged and the Sa02 was slightly improved at 73% (although the 
error of oximetry is + 5% at this Sa02) . One day after the 
conclusion of the study, the subject presented to the medical camp 
with markedly increased right sided rales, an Sa02 of 65%, and 
increased dyspnea, all consistent with HAPE. In addition to the 
two doses of acetazolamide 250 mg the subject had received as part 
of the study, he also reported taking another 250 mg of 
acetazolamide shortly before presenting with HAPE 48 hours after 
entering the study, and 40 hours after the last study dose of 
acetazolamide. The subject remained at 4400 m for another day, and 
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was treated with low flow oxygen overnight. He descended with a 
guide from his party the next day without complications. 
Table 13. Progression from AMS to HAPE in Subject 7 
AMS 
0 hours 24 hours 
HAPE 
60 hours* 
AMS Score 3 1 HAPE 
Sa02% 67% 73% 73% 
PetC02 22.2 22.2 21.3 
PaC02 venous 25.7 28.9 
Pa02 
sample 
39.0 40.0 
(A-a)D02 14 .1 17.6 
(all values in torrs except Sa02 and symptom scores) 
* Subject slept overnight on low flow oxygen. 
Data on Pa02 and (A-a)D02 were obtained on subject 7 at 24 
and 60 hours after inclusion in this study, and surprisingly were 
not markedly different than arterial blood gases from other 
subjects in the study (Table 13). At 24 hours, Pa02 was 39.0 torr 
and (A-a)D02 was 14.1 torr. At 60 hours, Pa02 was 40 torr and (A- 
a)D02 was 17.6 torr. At 24 hours subject 7 had resolving AMS with 
a symptom score of 1 and some right middle lobe rales, and at 60 
hours he had dyspnea at rest with diffuse right sided rales. Yet 
his Pa02 and (A-a)D02 were not markedly different in contrast to 
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the change in his clinical presentation. Progression from AMS to 
HAPE in this case, then, was characterized by symptoms and not by 
objective measurements of Pa02 and (A-a)D02. 
Given this case, two contrasting conclusions could be made 
regarding acetazolamide prophylaxis for HAPE. Either acetazolamide 
was not effective in prophylaxis, or acetazolamide was effective 
and it was not until treatment was stopped that HAPE developed. 
The additional dose of acetazolamide given just before presentation 
with HAPE at 48 hours does not favor either conclusion. 
Pathophysiological events may have already occurred between 24 and 
48 hours making the additional acetazolamide dose treatment rather 
than prophylaxis. However, Gray also reported a case of HAPE in 
a subject taking acetazolamide prophylactically for AMS (21) and 
concluded that acetazolamide was not effective in prophylaxis for 
HAPE . 
Acetazolamide Prevention and Treatment of AMS: 
Acetazolamide prevents AMS when taken prior to ascent 
(8,30,57), and this study shows that acetazolamide treats AMS when 
taken after symptoms occur. This requires a redefinition of 
appropriate use of acetazolamide during ascent to high altitude. 
For abrupt ascent from sea level to very high altitude, such 
as may occur in air transport of rescue or military personnel. 
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prophylaxis for altitude illness is indicated. For more gradual 
ascent to altitude, however, prophylaxis is indicated only for 
individuals with a past history of AMS. This applies to the 
traveller flying from sea level to a ski resort in the Rocky 
Mountains who often misses the first day of skiing because of 
headache and lassitude, as well as to the high altitude climber 
who usually experiences AMS symptoms with ascents of 1000m in a 
single day. Recommended doses of acetazolamide are 125 to 250 mg 
twice daily beginning one day before ascent and continuing for the 
first day or two at altitude. A similar regimen should be used for 
reascent to higher altitudes. 
For climbers at extreme altitude or making fast alpine style 
ascents, acetazolamide prophylaxis for AMS is also indicated. In 
these situations impaired coordination from CNS symptoms of AMS 
might endanger both the climber and his or her companions. Still, 
adequate acclimatization prior to a fast ascent or during a climb 
at extreme altitude is preferable to acetazolamide prophylaxis. 
The risk of serious altitude illness in a setting where rescue may 
be impossible makes adequate acclimatization essential. 
For individuals without a past history of AMS acetazolamide 
need not be used prophylactically, but may be taken if symptoms 
occur. Doses of 125 to 250 mg twice daily continued for one or 
two days will speed acclimatization and relieve symptoms. If 
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symptoms do occur after ascent, and reascent to a higher altitude 
is anticipated later, then prophylactic therapy is indicated. 
For individuals whose only symptom is disturbed sleep, low 
dose (125 mg) acetazolamide in the evening will result in decreased 
sleep periodic breathing, improved nocturnal arterial oxygen 
saturation, and more restful sleep. Doses of 125 mg appear to be 
effective in improving sleep and result in less side effects, such 
as nocturnal diuresis that may itself * disturb sleep. Nocturnal 
headache also may be relieved with low dose acetazolamide and 
analgesics. 
Acetazolamide is indicated for the treatment of AMS and may 
be used when symptoms occur, rather than for prophylaxis, by the 
individual without a consistent history of AMS on ascent to 
altitude. However, adequate acclimatization is preferable because 
it decreases the risk of more serious altitude illness. Likewise, 
acetazolamide therapy for AMS is not a substitute for descent. 
When symptoms of AMS do not improve or suggest progression to HAPE 
or HACE, descent may be lifesaving. The most useful treatment 
application of acetazolamide might be to relieve symptoms enough 
to make descent possible in more severe cases of AMS. 
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